Glenmark Pharmaceuticals Limited 
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com 
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026  E: complianceofficer@glenmarkpharma.com 
To, 
The Manager ‚Äì Listing 
National Stock Exchange of India Ltd., 
 Plot No. C/1, G Block, 
Bandra Kurla Complex, 
Bandra (E), Mumbai ‚Äì 400 051. 
August 29, 2025 
To, 
 
Dy. General Manager 
Department of Corporate Services, 
BSE Ltd., 
P. J. Towers, Dalal Street, 
  
Fort, Mumbai ‚Äì 400 001. 
 
Ref: Scrip Code: 532296 
Ref: Scrip Name: GLENMARK 
Dear Sirs, 
Sub: Business Responsibility & Sustainability Report for F.Y. 2024-25 
Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) 
Regulations, 2015, we are enclosing herewith the Business Responsibility & Sustainability Report 
of the Company for F.Y. 2024-25. 
Kindly take the above information on record. 
Thanking You 
Yours Faithfully, 
For Glenmark Pharmaceuticals Limited 
Harish Kuber 
Company Secretary & Compliance Officer 
Encl: As above 
HARISH 
VINAYAK 
KUBER
Digitally signed 
by HARISH 
VINAYAK KUBER 
Date: 2025.08.29 
19:29:35 +05'30'
Integrated Annual Report FY 2025
217
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
Business Responsibility and 
Sustainability Report FY 2025
SECTION A: GENERAL DISCLOSURES 
I.  
Details of the listed entity 
1
Corporate Identity Number (CIN) of the Company
/0+3/&b
2
Name of the Company
*OHQPDUN3KDUPDFHXWLFDOV/LPLWHGb
3
Year of incorporation
b
4
5HJLVWHUHGRŸ∏FHDGGUHVV
B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, 
0XPEDL0DKDUDVKWUD,QGLDb
5
&RUSRUDWHRŸ∏FHDGGUHVV
Glenmark House, B. D. Sawant Marg, Chakala, 
2Ÿµ:HVWHUQ([SUHVV+LJKZD\$QGKHUL(
0XPEDL0DKDUDVKWUD,QGLDb
6
(PDLO
FRPSOLDQFHRŸ∏FHU#JOHQPDUNSKDUPDFRP 
7
Telephone
b
8
:HEVLWH
http://www.glenmarkpharma.com
9
7KHŸ∂QDQFLDO\HDUIRUZKLFKUHSRUWLQJLVEHLQJGRQH
VW$SULOWRVW0DUFKb
10
Name of the stock exchange(s) where shares are 
listed 
1DWLRQDO6WRFN([FKDQJHRI,QGLD/LPLWHG16(
%6(/LPLWHG%6(b
11
Paid-up capital 
INR 282.19 M
12
Name and contact details of the person who may be 
contacted in case of any queries on the BRSR report 
Mr. Harish Kuber 
&RPSDQ\6HFUHWDU\	&RPSOLDQFH2Ÿ∏FHU
FRPSOLDQFHRŸ∏FHU#JOHQPDUNSKDUPDFRP 
b
13
Reporting boundary 
The disclosure under this BRSR is on a standalone* basis 
XQOHVVRWKHUZLVHVWDWHGb
14
Name of assurance provider
'19%XVLQHVV$VVXUDQFH,QGLD3ULYDWH/LPLWHG
15
Type of assurance obtained
Reasonable level of assurance for BRSR core indicators
 
*Standalone year pertains to Glenmark Pharmaceuticals Limited India.
II. 
Products/services 
 
16. 
Details of business activities (accounting for 90% of the turnover): 
S. No. 
Description of Main 
Activity 
Description of Business Activity 
% of Turnover 
of the entity 
1.
Pharmaceuticals 
The 
Company 
specializes 
in 
research, 
development, 
manufacturing, and sales of a diverse range of pharmaceutical 
products, including branded generics, generics, specialty 
medications, and over the counter (OTC) treatments. The 
Company's expertise spans across multiple therapeutic areas, 
including dermatology, respiratory health, oncology, cardiology, 
diabetes, gynecology, gastroenterology, and anti-infectives, 
among others.
100%
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
218
 
17. 
Products/Services sold by the entity (accounting for 90% of the entity‚Äôs Turnover): 
S. No. 
Product/Service 
NIC Code 
% of total turnover
contributed 
1.
The Company's primary products and services, accounting 
for 90% of its turnover, include the research, development, 
manufacturing, and sale of branded generics, generics, 
specialty 
medicines, 
and 
over 
the 
counter 
(OTC) 
SKDUPDFHXWLFDOSURGXFWV7KHVHRŸµHULQJVVSDQDZLGHUDQJH
of therapeutic areas such as dermatology, respiratory care, 
oncology, cardiology, diabetes management, gynecology, 
gastroenterology, and anti-infective treatments, among 
others.
210
100% 
III. Operations 
 

1XPEHURIORFDWLRQVZKHUHSODQWVDQGRURSHUDWLRQVRŸ∏FHVRIWKHHQWLW\DUHVLWXDWHG
Location 
Number of plants 
1XPEHURIRŸ∏FHV
Total 
National 
8
15
23 
International 
3
48
51
 
 
Note:$SDUWIURPWKHDERYHRŸ∏FHDQGSODQWV*OHQPDUN3KDUPDFHXWLFDOV/LPLWHGWKH&RPSDQ\KDVWKHIROORZLQJ
facilities in India: 
 
 
‚Ä¢ 
3 research and development centers located at Sinnar, Taloja and Mahape to drive innovation for development 
of new pharmaceutical products. 


»ç
ZDUHKRXVHVDUHORFDWHGDW,QGRUH+RZUDK3DQFKNXOD	%KLZDQGLWRHQKDQFHGLVWULEXWLRQHŸ∏FLHQF\LQYHQWRU\
PDQDJHPHQWDQGIXOŸ∂OOLQJWKHUHJXODWRU\FRPSOLDQFHUHTXLUHPHQWVVXFKDV*RRG'LVWULEXWLRQ3UDFWLFH*'3
etc.
 
19. 
Markets served by the entity: 
 
 
a. 
Number of locations 
Locations 
Number 
National (No. of States) 
28 states and 8 union territories
International (No. of Countries) 
More than 80


E
:KDWLVWKHFRQWULEXWLRQRIH[SRUWVDVDSHUFHQWDJHRIWKHWRWDOWXUQRYHURIWKHHQWLW\"



2XUSURGXFWVDUHH[SRUWHGWRPRUHWKDQFRXQWULHVZLWKDVWURQJIRRWSULQWLQ86(XURSH$VLD5XVVLDDQG%UD]LO
etc. of our total standalone turnover of INR 92,264.09 Mn. the percentage of revenue from exports accounted for 
51.39% INR 47,416.62 Mn. 


F
$EULHIRQW\SHVRIFXVWRPHUV



:LWKDGLYHUVHSRUWIROLRRISKDUPDFHXWLFDOSURGXFWVWKH&RPSDQ\VHUYHVDEURDGFXVWRPHUEDVHDFURVVNH\
therapeutic areas such as dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, 
and anti-infectives. These products address the needs of a wide range of patients, facilitated through a 
comprehensive distribution network that includes wholesalers, distributors, pharmacy chains, healthcare 
providers, government institutions, and hospitals. Furthermore, the Company extends its global presence by 
exporting products to international markets through both its subsidiaries and third-party distributors.
Integrated Annual Report FY 2025
219
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
IV. Employees 
 
20. 
Details as at the end of the Financial Year: 


D
(PSOR\HHVDQGZRUNHUVLQFOXGLQJGLŸµHUHQWO\DEOHG
S. 
No. 
Particulars 
Total 
(A) 
Male 
Female 
No. (B) 
% (B / A) 
No. (C) % (C / A) 
EMPLOYEES 
1. 
Permanent (D) 
11,641 
10,775 
93 
866 
7 
2. 
2WKHUWKDQ3HUPDQHQW(
311 
241 
77 
70 
23 
3. 
Total employees (D + E) 
 11,952 
 11,016 
 92 
 936 
8 
WORKERS1 
4. 
Permanent (F) 
 1,836 
 1,799 
 98 
 37 
 2 
5. 
Other than Permanent (G) 
 2,835 
 2,610 
 92 
 225 
 8 
6. 
Total workers (F + G) 
 4,671 
 4,409 
 94 
 262 
 6 


E
'LŸµHUHQWO\DEOHGHPSOR\HHVDQGZRUNHUV
S. 
No 
Particulars 
Total 
(A) 
Male 
Female 
No. (B) 
% (B / A) 
No. (C) 
% (C / A) 
DIFFERENTLY ABLED EMPLOYEES
1. 
Permanent (D) 
74 
61 
82 
13 
18 
2. 
2WKHUWKDQ3HUPDQHQW(
1$
1$
1$
1$
1$
3. 
7RWDOGLŸµHUHQWO\DEOHGHPSOR\HHV'(
74 
61 
82 
13 
18 
DIFFERENTLY ABLED WORKERS
4. 
Permanent (F) 
14 
13 
93 
1 
7 
5. 
Other than Permanent (G) 
1$
1$
1$
1$
1$
6. 
7RWDOGLŸµHUHQWO\DEOHGZRUNHUV)*
14 
13 
93 
1 
7 
 
21. 
Participation/Inclusion/Representation of women 
 
Total 
(A) 
No. and percentage of Females 
No. (B) 
% (B / A) 
Board of Directors 
9
4
44
Key Management Personnel 
4
1
25
 
22. 
Turnover rate for permanent employees and workers 
 
 
(Disclose trends for the past 3 years) 
FY 2024 ‚Äì 25
FY 2023-24
FY 2022-23
Male 
Female 
Total 
Male 
Female 
Total 
Male 
Female
Total 
Permanent Employees 
15%
17%
15%
18%
19%
18%
19%
24%
19%
Permanent Workers 
17%
19%
17%
15%
6%
15%
24%
14%
24%
V. 
Holding, Subsidiary and Associate Companies (including joint ventures) 
 
23. 
(a) 
Names of holding / subsidiary / associate companies / joint ventures 



7KHGHWDLOVRIVXEVLGLDU\DVVRFLDWHMRLQWYHQWXUHFRPSDQLHVDUHSURYLGHGLQ)RUP$2&DVDQQH[XUHLQWKH
%RDUG»ÖV5HSRUWDQGWKLVIRUPVSDUWRIWKH,QWHJUDWHG$QQXDO5HSRUW
1 GRI 2-8
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
220
VI.  CSR Details 

 L
:KHWKHU&65LVDSSOLFDEOHDVSHUVHFWLRQRI&RPSDQLHV$FW<HV
 
 
ii. 
Turnover (in `): 92,264.09 Mn
 
 
iii. 
Net worth (in `): 245,039.56 Mn
VII.   Transparency and Disclosures Compliances 
 
25. 
Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible 
Business Conduct: 
Stakeholder group 
from whom complaint 
is received
Grievance Redressal 
Mechanism in Place (Yes/
No) If yes, then provide 
web-link for grievance 
redress policy
FY 2024 ‚Äì 25
FY 2023 - 24
Number of 
complaints 
Ÿ∂OHG
during the 
year
Number of 
complaints 
pending
resolution
at close of 
the year
Number of 
complaints 
Ÿ∂OHG
during the 
year
Number of 
complaints 
pending
resolution
at close of 
the year
Communities 
https://glenmarkpharma.
com/about-us/governance/ 
Nil 
Nil
Nil
Nil 
Investors 
Nil
Nil
Nil
Nil
Shareholders
2
Nil
6
Nil
(PSOR\HHVDQGZRUNHUV
19
3
18
3
Customers
3,717
365
2,666
356
Value Chain Partners 
3
Nil
Nil
Nil
Other (Please Specify)
7
1
3
Nil


:HFRQGXFWRXUEXVLQHVVZLWKLQWHJULW\DQGWUDQVSDUHQF\XSKROGLQJWKHKLJKHVWVWDQGDUGVDVGHŸ∂QHGE\RXUFRUH
values and the Glenmark Code of Conduct. Our guiding policies, including grievance redressal mechanisms, are 
available at https://glenmarkpharma.com/about-us/governance/, with additional internal policies accessible via the 
&RPSDQ\»ÖVLQWUDQHW)RUFXVWRPHUJULHYDQFHVUHIHUWR3ULQFLSOHHVVHQWLDOLQGLFDWRURIWKLVUHSRUW$GGLWLRQDOO\ZH
provide a dedicated platform for reporting ethical and compliance concerns at https://glenmarkpharma.com/ethics-
compliance/. 
 
26. 
Overview of the entity‚Äôs material responsible business conduct issues 
 
 
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 
matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt 
RUPLWLJDWHWKHULVNDORQJZLWKLWVŸ∂QDQFLDOLPSOLFDWLRQV
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
1.
Product 
Quality, Safety 
and Recall 
Management 
5LVNb
Risk: Product quality, safety, 
and recall management 
SRVHVLJQLŸ∂FDQWULVNVIRURXU
Company due to their direct 
impact on patient health and 
UHJXODWRU\FRPSOLDQFH$Q\
lapse can lead to product 
recalls, legal liabilities, 
reputational damage, and 
Ÿ∂QDQFLDOORVVHV$GGLWLRQDOO\
the risk of counterfeit 
medicines undermines 
patient safety and erodes 
trust in our brand.
»ç
(VWDEOLVKHGFHQWUDOL]HG
Quality Management 
System accredited 
with ISO standards to 
maintain high-quality 
benchmarks across 
research, manufacturing, 
DQGGLVWULEXWLRQ:HDOVR
ensure strict adherence 
to Good Manufacturing 
3UDFWLFHV*03b
‚Ä¢ 
 Conduct rigorous 
audits of our third-
party suppliers and 
our pharmacovigilance 
activities help monitor 
and swiftly address
Negative: Non-
compliance with 
product quality 
standards can result 
in product recalls, 
Ÿ∂QDQFLDOORVVHVOHJDO
liabilities, and damage 
to our brand value and 
reputation.
Integrated Annual Report FY 2025
221
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
 
 product safety and 
quality issues, enhancing 
our overall assurance 
IUDPHZRUNb
‚Ä¢ 
 Regular testing is 
undertaken for all 
products prior to 
dispatch, to allow for 
timely correction, if 
required. 
b
Innovation and 
Research and 
'HYHORSPHQWb
2SSRUWXQLW\b
Opportunity: Innovation 
and the development of 
new products and therapies 
plays a critical role in 
enhancing our competitive 
edge, enabling expansion 
into new geographies 
and markets. This not 
only drives additional 
revenue and strengthens 
brand reputation but also 
demonstrates a strong 
commitment to addressing 
unmet medical needs and 
improving patient well-
EHLQJb
b
Positive: Innovation 
and development of 
new therapies drives 
additional revenue, 
enable long-term 
growth through 
patents, and support 
market expansion. 
$GLYHUVHSURGXFW
portfolio addressing 
key healthcare needs 
enhances brand 
reputation, while R&D 
investments open 
Ÿ∂QDQFLDORSSRUWXQLWLHV
through exclusivity, 
licensing, and strategic 
SDUWQHUVKLSVb
3.
$FFHVVDQG
$ŸµRUGDELOLW\RI
Medicines 
Opportunity 
2SSRUWXQLW\([SDQGLQJ
access to underserved 
markets presents a strong 
growth opportunity by 
increasing sales, revenue, 
and market share. 
(QKDQFLQJWKHDYDLODELOLW\
DQGDŸµRUGDELOLW\RI
medicines strengthens 
brand reputation and 
supports better public 
health outcomes. These 
HŸµRUWVDOVRDOLJQZLWKJOREDO
health priorities, enabling 
public-private partnerships, 
government tenders, and 
inclusion in national health 
programs, further driving 
EXVLQHVVJURZWKb
b
Positive: Focused 
HŸµRUWVIRUDFFHVVWR
DŸµRUGDEOHPHGLFLQHV
strengthens our 
customer base, 
enhances competitive 
advantage, and 
supports business 
expansion into 
new geographies, 
contributing to the our 
long-term sustainable 
growth.
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
222
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
b
Occupational 
Health, Safety 
DQG:HOOEHLQJb
5LVNb
5LVN(PSOR\HHVDQGZRUNHUV
may be exposed to toxic 
or hazardous chemicals, 
VROYHQWVDQG$FWLYH
Pharmaceutical Ingredients 
$3,VSRWHQWLDOO\OHDGLQJ
to occupational health 
LVVXHV:RUNSODFHVDIHW\
incidents and ergonomic 
risks further contribute to 
health and safety concerns. 
Inadequate awareness of 
operational hazards and 
LQVXŸ∏FLHQWWUDLQLQJWR
mitigate these risks can 
heighten vulnerabilities. 
$GGLWLRQDOO\RSHUDWLRQV
involving heavy equipment 
often expose workers to 
elevated temperatures, 
as well as chemical and 
physical hazards, increasing 
the overall risk to health and 
safety.
»ç
(QVXUHVWULFWFRPSOLDQFH
with health and safety 
laws, regulations, and 
guidelines through 
various proactive 
measures. These include 
the implementation of 
ISO 45001 and the British 
Safety Council‚Äôs 5-Star 
Safety System, along 
with alignment to global 
safety programs. 
‚Ä¢ 
 Regular health, safety, 
DQGŸ∂UHVDIHW\DXGLWVDUH
conducted to identify 
and mitigate risks. 
»ç
0RQWKO\UHYLHZVRI(+6
performance metrics, 
safety campaigns, and 
initiatives like the Safety 
Champion Program 
further strengthen safety 
culture.
‚Ä¢ 
 Mandatory use of 
33(IRUDOOSHUVRQQHO
entering plant 
premises reinforces 
our commitment to 
ZRUNSODFHVDIHW\b
Negative: Health and 
safety incidents can 
OHDGWRVLJQLŸ∂FDQW
Ÿ∂QDQFLDOLPSOLFDWLRQV
These may include 
UHJXODWRU\Ÿ∂QHVOHJDO
liabilities, increased 
insurance premiums, 
and costs related to 
medical treatment 
and compensation. 
Operational 
disruptions due to 
accidents can impact 
productivity and 
lead to delays in 
manufacturing and 
VXSSO\DŸµHFWLQJ
revenue.
Reputational damage 
may also result in loss 
of customer trust and 
LQYHVWRUFRQŸ∂GHQFH
potentially impacting 
market share and 
ORQJWHUPSURŸ∂WDELOLW\b
b
Human Capital 
0DQDJHPHQWb
2SSRUWXQLW\b
Opportunity: Human 
Capital Management is a 
key opportunity to drive 
long-term value. Hiring the 
right talent for the right 
roles improves productivity 
in plant operations, 
enables innovation in R&D, 
enhances product quality, 
and supports business 
expansion. Investing in 
a diverse and inclusive 
workforce, while fostering 
continuous employee 
growth, builds a resilient 
and high-performing 
organization capable of 
delivering on its mission 
HŸµHFWLYHO\b
b
Positive: Skilled and 
motivated employees 
enhance operational 
HŸ∏FLHQF\GULYH
innovation in research 
and development, 
and improve product 
quality, leading 
to faster time-to- 
market and higher 
competitiveness. 
Career growth 
initiatives also 
reduce turnover, 
lowering recruitment 
and training costs. 
Furthermore, a high-
performing workforce 
contributes directly 
to business growth, 
SURŸ∂WDELOLW\DQG
sustained market 
leadership.
Integrated Annual Report FY 2025
223
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
b
Sustainable 
Supply Chain 
Risk and 
2SSRUWXQLW\b
Risk: Supply chain 
GLVUXSWLRQVFDQVLJQLŸ∂FDQWO\
impact the timely supply and 
sales of products, leading to 
delays in delivery to patients 
and healthcare providers, 
which may hinder treatment 
processes. Such delays and 
product unavailability can 
DOVRQHJDWLYHO\DŸµHFWEUDQG
value and reputation.
2SSRUWXQLW\$QHŸ∏FLHQW
supply chain management 
system streamlines 
operations, reduces 
redundancies, and ensures 
HŸµHFWLYHORJLVWLFVDQG
inventory management. 
Strategic collaborations 
strengthen relationships 
with logistics partners, 
suppliers, distributors, 
and other stakeholders. 
$GGLWLRQDOO\RSWLPL]LQJ
resources within the supply 
chain helps minimize 
operational expenditure 
and conserve company 
resources.
‚Ä¢ 
 Implement risk 
mitigation plans for the 
LGHQWLŸ∂HGSRWHQWLDOULVNV
and vulnerabilities across 
our supply chain. 
»ç
$VVHVVDOOVXSSOLHUV
on parameters such 
as reliability, product 
quality, ethical practices, 
and compliance with 
international and local 
regulatory standards 
before onboarding and 
at regular intervals 
thereafter.
‚Ä¢ 
 Conduct periodic audits 
of suppliers and third-
party manufacturers 
to ensure consistent 
adherence to Glenmark‚Äôs 
quality, safety, and 
sustainability standards. 
,QFOXGH(6*FULWHULDLQ
DXGLWVFRSHb
‚Ä¢ 
 Leverage advanced 
digital tools and 
analytics for real-time 
monitoring of inventory, 
logistics, and supplier 
performance. Improve 
forecasting capabilities 
to anticipate and 
respond to potential 
GLVUXSWLRQVVZLIWO\b
‚Ä¢ 
 To reduce dependency 
on a single geography 
or supplier, we have 
FXOWLYDWHGDGLYHUVLŸ∂HG
VXSSOLHUEDVH:HDOVR
prioritize local sourcing. 
‚Ä¢ 
 Develop and routinely 
update contingency 
plans to ensure business 
continuity in the 
event of supply chain 
disruptions. This includes 
maintaining backup 
suppliers, alternate 
production facilities, and 
VWUDWHJLFEXŸµHUVWRFNVb
Negative: Supply 
chain disruptions 
can lead to delays 
in the procurement 
of raw materials, 
hindering production 
timelines and 
DŸµHFWLQJWKHWLPHO\
delivery of products 
to customers. This 
PD\VLJQLŸ∂FDQWO\
impact operational 
continuity, leading to 
reduced productivity 
and potentially 
diminishing our 
revenue generation 
FDSDELOLWLHVb
Positive: Sustainable 
supply chain 
management 
enhances the 
HŸ∏FLHQF\RIPDWHULDO
DQGSURGXFWŸ∑RZV
contributing to 
improved overall 
operational 
performance. 
Strengthening supply 
chain resilience helps 
prevent disruptions 
and ensures the 
consistent and 
timely delivery of 
products and services, 
reinforcing customer 
trust and business 
FRQWLQXLW\b
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
224
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
b
Data Privacy 
and Cyber 
6HFXULW\b
5LVNb
Risk: Cyberattacks can lead 
to the theft of sensitive data 
such as patient records, 
clinical results, proprietary 
research, and intellectual 
SURSHUW\FDXVLQJŸ∂QDQFLDO
losses, operational 
disruptions, and damage 
to brand reputation. 
Furthermore, failure to 
comply with data privacy 
ODZVOLNH+,3$$DQG*'35
may result in legal action 
and penalties. Inadequate 
security measures weaken 
competitive advantage 
and expose the Company 
WRVLJQLŸ∂FDQWULVNVERWK
Ÿ∂QDQFLDODQGUHSXWDWLRQDO
»ç
(VWDEOLVKHGDUREXVW,7
management system 
with layered controls, 
including multi-factor 
authentication, antivirus 
VRIWZDUHDQGŸ∂UHZDOOVWR
VDIHJXDUGGDWDb
»ç
(QIRUFHVWULFWDFFHVV
control mechanisms to 
ensure only authorized 
personnel can access 
FRQŸ∂GHQWLDOLQIRUPDWLRQb
‚Ä¢ 
 Limit data collection and 
retention of essential 
information to reduce 
WKHULVNRIEUHDFKHVb
»ç
(QVXUHFRPSOLDQFHZLWK
relevant data protection 
regulations such as 
*'35DQG+,3$$b
‚Ä¢ 
 Develop a 
comprehensive incident 
response plan with 
clear procedures for 
managing cybersecurity 
LQFLGHQWVb
‚Ä¢ 
 Conduct regular 
employee training on 
endpoint and network 
security, along with best 
practices to prevent IT 
WKUHDWVb
‚Ä¢ 
 Continuously monitor 
and analyze systems 
for new vulnerabilities 
through regular network 
and system scans.
Negative: Failure 
to comply with the 
Code of Conduct 
or local laws may 
result in regulatory 
penalties, operational 
GLVUXSWLRQVŸ∂QDQFLDO
ORVVHVDQGVLJQLŸ∂FDQW
UHSXWDWLRQDOGDPDJHb
b
Corporate 
Governance 
and Business 
(WKLFV
Risk and 
2SSRUWXQLW\b
Risk : Non-compliance with 
local laws and regulatory 
requirements, such as CGMP 
and CGLP, may result in 
KHIW\Ÿ∂QHVVDQFWLRQVRU
legal action. Violations of 
quality standards, unethical 
pricing, or neglect of safety 
protocols can compromise 
patient health, erode 
customer trust, and damage 
the Company'sreputation. 
$GGLWLRQDOO\XQGHUPLQLQJ
relationships with key 
stakeholders‚Äîincluding 
healthcare providers and 
regulatory
»ç
(VWDEOLVKDUREXVW
corporate governance 
structure with strong 
oversight of business 
strategy, ensuring 
compliance with all 
statutory and regulatory 
UHTXLUHPHQWVb
‚Ä¢ 
 Promote transparency 
through timely and 
accurate disclosure of 
Ÿ∂QDQFLDODQGQRQ
Ÿ∂QDQFLDOLQIRUPDWLRQ
by aligning with global 
UHSRUWLQJIUDPHZRUNVb
Negative: Non-
compliance with 
Code of conduct 
and violation of local 
laws could lead to 
imposition of penalties 
by regulatory 
agencies, business 
disruption, revenue 
loss and reputational 
risks. 
3RVLWLYH$VWURQJ
ethical and legally 
compliant corporate 
governance 
framework fosters 
stakeholder trust and 
strengthens our
Integrated Annual Report FY 2025
225
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
bodies‚Äîcan impact the 
Company‚Äôs credibility and 
ORQJWHUPEUDQGYDOXHb
Opportunity: Upholding 
high ethical standards and 
strict legal compliance, with 
integrity, transparency, 
and accountability helps 
build stakeholder trust and 
strengthens our reputation. 
Consistently maintaining 
ethical business practices 
aligned with our core values 
fosters a positive corporate 
culture, mitigates business 
risks, and supports long-
WHUPVXVWDLQDEOHJURZWKb
‚Ä¢ 
 Conduct regular internal 
and external audits to 
evaluate governance 
SUDFWLFHVŸ∂QDQFLDO
controls, and adherence 
to applicable laws and 
HWKLFDOVWDQGDUGVb
»ç
(QVXUHDZHOOEDODQFHG
board composition 
with a diverse skill set, 
including adequate 
representation of 
Independent Directors 
to safeguard stakeholder 
LQWHUHVWVb
»ç
(QIRUFHVWULFWFRPSOLDQFH
with the Glenmark Code 
of Conduct by providing 
regular training to 
employees across all 
OHYHOVb
‚Ä¢ 
 Maintain a strong 
ethical business culture 
by implementing 
comprehensive policies 
and procedures 
addressing ethical 
conduct and compliance 
REOLJDWLRQVb
»ç
(QVXUHWUDQVSDUHQF\LQ
critical business areas 
such as innovation, 
product development, 
and clinical trials to 
SUHYHQWFRQŸ∑LFWVRI
LQWHUHVWb
reputation. It also 
supports sustainable 
business growth by 
HŸµHFWLYHO\PLWLJDWLQJ
OHJDOŸ∂QDQFLDODQG
RSHUDWLRQDOULVNVb
b
&OLPDWH$FWLRQb
Risk and 
2SSRUWXQLW\b
Risk: Climate change 
poses both physical and 
transitional risks to us. 
Physically, the increasing 
frequency and severity of 
extreme weather events, 
VXFKDVŸ∑RRGVGURXJKWV
and heatwaves can directly 
disrupt our operations, supply 
chains, and infrastructure. 
Transition-related risks 
arise from the evolving 
regulatory landscape, where 
new environmental laws 
and stricter compliance 
requirements may
‚Ä¢ 
 Develop and implement 
a climate resilience 
strategy by identifying 
and addressing potential 
vulnerabilities within 
our operations and 
supply chain which will 
help ensure business 
continuity in the face 
of climate-related 
GLVUXSWLRQVb
‚Ä¢ 
 Reduction of greenhouse 
gas (GHG) emissions 
through adoption 
RIHQHUJ\HŸ∏FLHQW
practices,
1HJDWLYHb 
:HUHFRJQL]HWKDW
climate change 
can disrupt our 
operations and supply 
chain, leading to 
delays in procuring 
raw materials, 
interruptions in 
our manufacturing 
processes, and 
challenges in 
delivering products 
to our customers 
on time. These 
disruptions
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
226
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
necessitate changes in 
operational processes. These 
adjustments could lead to 
additional expenditures, 
LPSDFWLQJSURŸ∂WDELOLW\
Furthermore, the broader 
impacts of climate change 
may hinder our ability to 
H[SDQGRURSHUDWHHŸ∏FLHQWO\
LQDŸµHFWHGUHJLRQVWKHUHE\
posing a threat to long-term 
JURZWKb
Opportunity: Despite the 
risks, climate change also 
presents opportunities 
for us to strengthen our 
competitive position. By 
adopting sustainable and 
environmentally responsible 
practices, we can improve 
RSHUDWLRQDOHŸ∏FLHQF\
reduce energy and resource 
consumption, and ultimately 
lower costs over the long 
term. In addition, a strong 
sustainability strategy 
enhances our appeal to 
environmentally conscious 
stakeholders, including 
consumers, investors, 
and strategic partners. 
This growing interest in 
sustainable business practices 
can lead to increased brand 
value, market share, and 
long-term growth potential 
IRUXVb
 
 transitioning to cleaner 
fuels, and increasing 
the share of renewable 
energy in the overall 
energy mix. These 
measures will contribute 
to a lower carbon 
footprint and long-term 
VXVWDLQDELOLW\b
‚Ä¢ 
 By strengthening supply 
chain resilience against 
climate-related risks by 
diversifying suppliers 
and sourcing locations, 
we will mitigate 
disruptions and maintain 
operational stability even 
during extreme climate 
HYHQWVb
FDQDŸµHFWRXU
HŸ∏FLHQF\FXVWRPHU
satisfaction, and 
overall business 
SHUIRUPDQFHb
3RVLWLYHb 
$WWKHVDPHWLPH
we see a valuable 
opportunity to 
build operational 
resilience by adopting 
sustainable practices. 
By proactively 
addressing both 
the physical and 
transitional risks of 
climate change, we 
aim to ensure the 
long-term stability and 
sustainable growth of 
RXUEXVLQHVVb
b
Natural 
Resource 
0DQDJHPHQWb
Risk and 
2SSRUWXQLW\b
Risk: Responsible 
management of natural 
resources is essential to 
ensure environmental 
compliance, protect public 
health, and maintain 
RSHUDWLRQDOHŸ∏FLHQF\
Improper disposal of 
wastewater and waste, 
along with excessive air 
pollutant emissions, can 
lead to legal penalties and 
damage our reputation. 
Moreover, high water 
consumption and poor air 
quality management pose 
risks to both our productivity 
and the well-being of 
workers and surrounding 
communities. By adhering to 
environmental
‚Ä¢ 
 Implement water 
conservation measures 
by deploying water-
HŸ∏FLHQWHTXLSPHQWDQG
optimizing processes to 
UHGXFHFRQVXPSWLRQb
»ç
(QVXUHSURSHUWUHDWPHQW
and reuse of wastewater 
across all our operations 
to minimize dependency 
RQIUHVKZDWHUUHVRXUFHVb
‚Ä¢ 
 Long-term plan is to 
install Zero Liquid 
Discharge systems 
across all our 
manufacturing sites.
Negative: Improper 
management of 
natural resources 
can expose us to 
FRQVLGHUDEOHŸ∂QDQFLDO
ULVNV$QRYHUUHOLDQFH
on local water 
sources may lead to 
supply shortages and 
costly operational 
disruptions. Similarly, 
improper waste 
disposal practices 
increase the likelihood 
of legal action, 
Ÿ∂QHVDQGKLJKHU
compliance costs, 
while also damaging 
our reputation and 
customer
Integrated Annual Report FY 2025
227
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
Sr. 
No. 
Material 
LGHQWLŸ∂HG
issue 
Indicate 
whether 
risk or 
opportunity 
(R/O) 
Rationale for identifying 
the risk / opportunity 
In case of risk, approach 
to adapt or mitigate 
Financial 
implications of the 
risk or opportunity 
(Indicate Positive 
or negative 
implications) 
regulations and adopting 
sustainable practices 
in water, waste, and air 
pollution management, we 
can mitigate these risks 
and promote long-term 
RSHUDWLRQDOUHVLOLHQFHb
b
Opportunity: By improving 
ZDWHUHŸ∏FLHQF\DGRSWLQJ
sustainable waste 
management practices like 
the 3Rs (Reduce, Reuse, 
Recycle), and implementing 
advanced air pollution 
control technologies, we 
can conserve resources 
and reduce operational 
FRVWV(PEUDFLQJUHQHZDEOH
energy and innovative 
solutions not only helps 
mitigate environmental 
risks but also opens 
avenues for regulatory 
incentives, carbon credits, 
and enhanced corporate 
reputation. These initiatives 
support long-term 
sustainability while driving 
operational excellence and 
VWDNHKROGHUWUXVWb
‚Ä¢ 
 Maintain a comprehensive 
water inventory and 
regularly monitor our 
performance on water 
FRQVHUYDWLRQLQLWLDWLYHVb
‚Ä¢ 
 Promote waste recycling 
to lower our reliance on 
virgin natural resources 
and reduce environmental 
LPSDFWb
»ç
$GRSWFRSURFHVVLQJ
methods for waste with 
FDORULŸ∂FYDOXHWRUHFRYHU
HQHUJ\DQGPLQLPL]HODQGŸ∂OO
GLVSRVDOb
»ç
(QVXUHIXOOFRPSOLDQFH
with all applicable waste 
management regulations 
DQGKD]DUGRXVZDVWHUXOHVb
‚Ä¢ 
 Innovate continuously to 
reduce waste generation 
during manufacturing, 
packaging, and other 
RSHUDWLRQDODFWLYLWLHVb
‚Ä¢ 
 Track and review our waste 
management performance, 
including metrics on 
waste reused, recycled, 
co-processed, and safely 
GLVSRVHGb
‚Ä¢ 
 Invest in advanced 
air pollution control 
technologies and 
monitor emissions to 
ensure compliance with 
HQYLURQPHQWDOVWDQGDUGVb
‚Ä¢ 
 Regularly assess and 
improve air quality 
management practices to 
safeguard worker health 
and minimize community 
LPSDFWb
»ç
(QJDJHZLWKUHJXODWRU\
bodies proactively to stay 
updated on environmental 
requirements and leverage 
DQ\DYDLODEOHLQFHQWLYHVb
‚Ä¢ 
 Foster a culture of 
sustainability and 
environmental responsibility 
across all levels of the 
RUJDQL]DWLRQb
trust‚Äîfactors that can 
undermine long-term 
Ÿ∂QDQFLDOSHUIRUPDQFH
$GGLWLRQDOO\IDLOLQJ
to adequately control 
air emissions risks 
incurring regulatory 
penalties and 
expensive remediation 
HŸµRUWV7KLVFDQ
also harm public 
perception, which 
may negatively impact 
brand value and 
restrict future growth 
opportunities. 
b
3RVLWLYH(ŸµHFWLYH
natural resource 
management across 
water, waste, and 
air pollution plays a 
vital role in reducing 
costs and enhancing 
SURŸ∂WDELOLW\%\
conserving and 
reusing water, we can 
VLJQLŸ∂FDQWO\ORZHU
procurement expenses 
while also minimizing 
operational risks 
linked to water 
scarcity. In parallel, 
recycling waste not 
only helps conserve 
resources but also 
creates additional 
revenue streams and 
reduces the costs 
associated with waste 
disposal. Furthermore, 
investing in air 
pollution controls 
ensures compliance 
with environmental 
regulations, helping 
DYRLGFRVWO\Ÿ∂QHV
and operational 
disruptions. 
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
228
SECTION B: MANAGEMENT AND PROCESS DISCLOSURES 
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and management processes 
1. 
a. 
 Whether your entity‚Äôs policy/policies 
cover each principle and its core 
elements of the NGRBCs. (Yes/No)
Yes
 
b. 
 Has the policy been approved by the 
Board? (Yes/No) 
Yes
 
c. 
Web Link of the Policies, if available 
3ULQFLSOH(WKLFVWUDQVSDUHQF\
‚Ä¢ 
 Code of Conduct (https://glenmarkpharma.com/code-of-conduct/) 
‚Ä¢ 
 Board Diversity Policy (https://glenmark.b-cdn.net/gpl_pdfs/about_
us/Board%20Diversity%20Policy.pdf) 
»ç
$QWL %ULEHU\ DQG $QWL&RUUXSWLRQ 3ROLF\ $YDLODEOH RQ FRPSDQ\»ÖV
intranet) 
»ç
&RGHRI(WKLFV$YDLODEOHRQ&RPSDQ\»ÖVLQWUDQHW
Principle 2: Product and service responsibility
»ç
(QYLURQPHQWDO +HDOWK 	 6DIHW\ 3ROLF\ https://glenmarkpharma.
com/ responsibility/our-policy/)
Principle 3: Human resources
‚Ä¢ 
 Occupational Health and Safety Policy (https://glenmarkpharma.
com/ responsibility/our-policy/) 
»ç
(QYLURQPHQWDO +HDOWK DQG 6DIHW\ 3ROLF\ https://glenmarkpharma.
com/ responsibility/our-policy/) 
‚Ä¢ 
 Nomination and Remuneration Policy (https://glenmark.b-cdn.net/
gpl_pdfs/about_us/nomination_and_remuneration_policy.pdf) 
»ç
:KLVWOHEORZHU
3ROLF\
https://glenmarkpharma.com/about-us/
governance/)
‚Ä¢ 
 Code of Conduct (https://glenmarkpharma.com/code-of-conduct/) 
»ç
5HGUHVVDO 0HFKDQLVP IRU (PSOR\HH $YDLODEOH RQ &RPSDQ\»ÖV
intranet) 
Principle 
4: 
Responsive 
to 
stakeholders, 
particularly the marginalized
‚Ä¢ 
 Code of Conduct (https://glenmarkpharma.com/code-of-conduct/) 
»ç
&RGHRI(WKLFV$YDLODEOHRQ&RPSDQ\»ÖVLQWUDQHW
»ç
5HGUHVVDO 0HFKDQLVP IRU (PSOR\HH $YDLODEOH RQ FRPSDQ\»ÖV
intranet) 
‚Ä¢ 
 Corporate Social Responsibility Policy (https://glenmarkpharma.
com/about-us/governance/)
Principle 5: Respect for human rights
‚Ä¢ 
 Human Rights Policy (https://glenmark.b-cdn.net/gpl_pdfs/about_
XV+XPDQ5LJKWV3ROLF\B$SGI) 
»ç
:KLVWOHEORZHU
3ROLF\
https://glenmarkpharma.com/about-us/
governance/)
»ç
&RGHRI(WKLFV$YDLODEOHLQ&RPSDQ\»ÖVLQWUDQHW
‚Ä¢ 
 Code of Conduct (https://glenmarkpharma.com/code-of-conduct/) 
3ULQFLSOH(QYLURQPHQWDOUHVSRQVLELOLW\
»ç
(QYLURQPHQW 3ROLF\ https://glenmarkpharma.com/responsibility/
our-policy/) 
‚Ä¢ 
 Occupational Health and Safety Policy (https://glenmarkpharma.
com/ responsibility/our-policy/)
‚Ä¢ 
 Biodiversity 
Policy 
(https://glenmark.b-cdn.net/gpl_pdfs/
responsibility/employee/Biodiversity%20Policy.pdf)
»ç
:DWHU 3ROLF\ https://glenmark.b-cdn.net/gpl_pdfs/responsibility/
HPSOR\HH:DWHU3ROLF\SGI)
Principle 7: Public policy advocacy
‚Ä¢ 
 Code of Conduct (https://glenmark.b-cdn.net/gpl_pdfs/about_us/ 
GlenmarkPharma_Code_of_Conduct.pdf) 
»ç
&RGHRI(WKLFV$YDLODEOHRQ&RPSDQ\»ÖVLQWUDQHW
Principle 8: Inclusive growth
Corporate Social Responsibility Policy (https://glenmark.b-cdn.net/gpl_
pdfs/ about_us/CSR%20Policy.pdf)
Principle 9: Customer engagement
,73ROLF\$YDLODEOHRQWKH&RPSDQ\»ÖVLQWUDQHW
Code 
of 
Conduct 
(https://glenmark.b-cdn.net/gpl_pdfs/about_us/ 
GlenmarkPharma_Code_of_Conduct.pdf)
Integrated Annual Report FY 2025
229
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
2. 
 Whether the entity has translated the 
policy into procedures. (Yes/No)
Yes
3. 
 Do the enlisted policies extend to your 
value chain partners? (Yes/No) 
Yes

1DPHRIWKHQDWLRQDODQGLQWHUQDWLRQDOFRGHVFHUWLŸ∂FDWLRQVODEHOVVWDQGDUGVHJ)RUHVW6WHZDUGVKLS&RXQFLO
Fairtrade, Rainforest Alliance, Trustee) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and 
mapped to each principle. 
 
 The Company adheres to CGMP standards and adopted TCFD apart from accreditations by Central Drugs Standard Control 
Organisation (CDSCO: India), Science Based Targets Initiative (SBTi), Taskforce on Nature-related Financial Disclosures 
71)',62	DQGLQWHUQDWLRQDOUHJXODWRU\DXWKRULWLHVVXFKDV86)'$:+2HWF

6SHFLŸ∂FFRPPLWPHQWVJRDOVDQGWDUJHWVVHWE\WKHHQWLW\ZLWKGHŸ∂QHGWLPHOLQHVLIDQ\

3OHDVHUHIHUWRWKH,QWHJUDWHG5HSRUWIRU(6*UHODWHGFRPPLWPHQWVJRDOVDQGWDUJHWV

3HUIRUPDQFHRIWKHHQWLW\DJDLQVWVSHFLŸ∂FFRPPLWPHQWVJRDOVDQGWDUJHWVDORQJZLWKUHDVRQVLQFDVHWKHVDPH
are not met.

3OHDVHUHIHUWKH,QWHJUDWHG5HSRUWIRUWKHSHUIRUPDQFHRIWKHHQWLW\RQ(6*UHODWHGFRPPLWPHQWVJRDOVDQGWDUJHWV
Governance, leadership and oversight 
7. 
 Statement by director responsible for the business responsibility report, highlighting ESG related challenges, 
WDUJHWVDQGDFKLHYHPHQWVOLVWHGHQWLW\KDVŸ∑H[LELOLW\UHJDUGLQJWKHSODFHPHQWRIWKLVGLVFORVXUH
 
 Refer to the message from the Chairman & Managing Director in the Integrated Report of Glenmark Pharmaceuticals 
Limited.
8. 
 Details 
of 
the 
highest 
authority 
responsible 
for 
implementation 
and 
oversight of the Business Responsibility 
policy. 
Glenn Saldanha 
Chairman & Managing Director

'RHVWKHHQWLW\KDYHDVSHFLŸ∂HG&RPPLWWHH
of the Board/ Director responsible for 
decision making on sustainability related 
issues? (Yes / No). If yes, provide details. 
<HV*OHQPDUN3KDUPDFHXWLFDOV/LPLWHGKDVHVWDEOLVKHGDGHGLFDWHG(6*
Committee, overseen by the Board, to guide and monitor progress towards 
LWV (6* SULRULWLHV FRPPLWPHQWV JRDOV DQG WDUJHWV 7KH &RPPLWWHH
ensures active and consistent engagement from senior management 
LQDGGUHVVLQJHPHUJLQJ(6*ULVNVDQGLGHQWLI\LQJQHZRSSRUWXQLWLHV,WV
IRFXVLVRQHPEHGGLQJ(6*FRQVLGHUDWLRQVDFURVVNH\EXVLQHVVIXQFWLRQV
including stakeholder relations, risk management, manufacturing 
processes, workforce engagement, and supply chain operations. The 
Committee plays a crucial role in assessing the advancement of the 
&RPSDQ\»ÖV(6*VWUDWHJ\ZKLFKLVGHVLJQHGWRGHOLYHUSRVLWLYHRXWFRPHV
for the economy, environment, and society. Detailed information about 
WKH(6*&RPPLWWHHFDQEHIRXQGLQWKH&RUSRUDWH*RYHUQDQFHVHFWLRQ
10. Details of Review of NGRBCs by the Company:
Indicate whether review was undertaken by Director / 
Committee of the Board/ Any other Committee
Subject for Review
P1
P2
P3
P4
P5
P6
P7
P8
P9
1 
 Performance against above policies and follow up 
action 
Yes
2 
 Compliance with statutory requirements of relevance 
WR WKH SULQFLSOHV DQG UHFWLŸ∂FDWLRQ RI DQ\ QRQ
compliances 
Yes
11.  Has 
the 
entity 
carried 
out 
independent 
assessment/ evaluation of the working of its 
policies by an external agency? (Yes/No). If yes, 
provide the name of the agency. 
No
12. If answer to question (1) above is ‚ÄúNo‚Äù i.e. not all Principles are covered by a policy, reasons to be stated: 
 
No
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
230
SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE 
PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a manner that is 
Ethical, Transparent and Accountable. 
Essential Indicators

3HUFHQWDJHFRYHUDJHE\WUDLQLQJDQGDZDUHQHVVSURJUDPPHVRQDQ\RIWKHSULQFLSOHVGXULQJWKHŸ∂QDQFLDO\HDU
Segment
Total number 
of training and 
awareness 
programs held
Topics / principles covered under the training and its 
impact
% age of persons in 
respective category 
covered by awareness 
programmes
Board of Directors 
Key Managerial 
Personnel
7
7
Familiarisation/ 
awareness 
programmes 
for 
the 
Board of Directors/ KMPs of the Company are done 
periodically as part of Board process covering various 
areas pertaining to the business, strategy,
risks, operations, regulations, code of business conduct 
and ethics, economy and environmental, social and 
governance parameters. In addition,
frequent updates are shared with all the Board 
members/ KMPs to appraise them of developments 
in the Company, key regulatory changes, risks, 
compliances and legal cases.
100%
100%
(PSOR\HHV
other than
BoD and
KMPs
2,013
3UHYHQWLRQ RI 6H[XDO +DUDVVPHQW DW :RUNSODFH
326+ ,&& 0HPEHU %LRGLYHUVLW\ 3ROLF\ (QYLURQPHQW
Health and Safety, Health and Hygiene, Occupational 
Health Safety, HR Induction Module, HR Policy, Privacy 
/DERU 5HODWLRQV (PHUJHQF\ (YDFXDWLRQ 3ROLF\ 2QVLWH
(PHUJHQF\3UHSDUHGQHVV3URFHGXUHIRU)DFWRU\6HFXULW\
System, Road Safety, Lock out Tag out Procedure, Code 
RI (WKLFV DQG 3URIHVVLRQDO &RQGXFW 'RQDWLRQ 3ROLF\
Suspected Fraud, Misconduct, Serious Breach and/or 
persistent Non-compliance, Meeting with Regulatory 
$XWKRULWLHV 0HGLFDO &KHFNXS 3URFHGXUH IRU +DQGOLQJ
Complaints by Volunteer / Subjects, Privacy and 
3URWHFWLRQ RI 3HUVRQDOO\ ,GHQWLŸ∂DEOH ,QIRUPDWLRQ3,,
'DWD 3URWHFWLRQ DQG 3ULYDF\  3URFHGXUH RI (QWU\ DQG
([LWDW0LFURELRORJ\/DE4F'HSDUWPHQW)DFWRULHVHWF
97%
:RUNHUV
100%

'HWDLOVRIŸ∂QHVSHQDOWLHVSXQLVKPHQWDZDUGFRPSRXQGLQJIHHVVHWWOHPHQWDPRXQWSDLGLQSURFHHGLQJVE\WKH
HQWLW\RUE\GLUHFWRUV.03VZLWKUHJXODWRUVODZHQIRUFHPHQWDJHQFLHVMXGLFLDOLQVWLWXWLRQVLQWKHŸ∂QDQFLDO\HDU
in the following format 

1RWHWKHHQWLW\VKDOOPDNHGLVFORVXUHVEDVHGRQPDWHULDOLW\DVVSHFLŸ∂HGLQ5HJXODWLRQRI6(%,/LVWLQJ2EOLJDWLRQVDQG
Disclosure Obligations) Regulations, 2015 and as disclosed on the entity‚Äôs website): 
 
Nil
3. 
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or 
non-monetary action has been appealed. 

1RW$SSOLFDEOH
4. 
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide 
a web-link to the policy. 

<HV*OHQPDUNKDVD*OREDO$QWL%ULEHU\DQG$QWL&RUUXSWLRQ»à$%$&»âSROLF\7KLVSROLF\LVJOREDOLQVFRSHDQGDSSOLHVWRDOO
employees of Glenmark Pharmaceuticals Limited, and Business Partners engaged in activities with Glenmark. Glenmark‚Äôs 
&RGHRI&RQGXFWVWDWHVWKHZD\ZHZRUNDQGGREXVLQHVVWKH$%$&SROLF\HQVXUHVWKDW*OHQPDUN»ÖVEXVLQHVVLVFRQGXFWHG
LQDOHJDODQGVRFLDOO\UHVSRQVLEOHPDQQHU7KH$%$&SROLF\FRYHUVWKHSULQFLSOHVDQGUHTXLUHPHQWVRI$%$&LQFOXGLQJ
PDLQWHQDQFHRIEXVLQHVVGRFXPHQWDWLRQDQGŸ∂QDQFLDOUHFRUGV2XU&RGHRI&RQGXFWH[SHFWVWKDWZHKRQRU$%$&ODZV
DQGRXU$%$&SROLF\DOLJQVZLWKDOOUHOHYDQWLQWHUQDWLRQDODQGORFDO$%$&ODZV%H\RQG(QJOLVKWKHSROLF\LVDOVRDYDLODEOHLQ
Polish, Czech, Portuguese, Russian, Slovakian and Spanish languages on our intranet. Training on this policy is part of the 
Integrated Annual Report FY 2025
231
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
LQGXFWLRQSURFHVVIRUDOOQHZ(PSOR\HHV$OOH[LVWLQJ(PSOR\HHVUHFHLYHUHJXODUWUDLQLQJRQKRZWRLPSOHPHQWDQGDGKHUH
to this policy. 
 
https://glenmarkpharma.com/code-of-conduct/
5. 
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement 
agency for the charges of bribery/ corruption: 
Particulars
FY 2024-25
FY 2023-24
Directors 
Nil 
Nil
KMPs 
(PSOR\HHV
:RUNHUV

'HWDLOVRIFRPSODLQWVZLWKUHJDUGWRFRQŸ∑LFWRILQWHUHVW
Particulars
FY 2024-25
FY 2023-24
1XPEHURIFRPSODLQWVUHFHLYHGLQUHODWLRQWRLVVXHVRI&RQŸ∑LFWRI,QWHUHVW
of the Directors
Nil
Nil
1XPEHURIFRPSODLQWVUHFHLYHGLQUHODWLRQWRLVVXHVRI&RQŸ∑LFWRI,QWHUHVW
of the KMPs

3URYLGHGHWDLOVRIDQ\FRUUHFWLYHDFWLRQWDNHQRUXQGHUZD\RQLVVXHVUHODWHGWRŸ∂QHVSHQDOWLHVDFWLRQWDNHQE\
UHJXODWRUVODZHQIRUFHPHQWDJHQFLHVMXGLFLDOLQVWLWXWLRQVRQFDVHVRIFRUUXSWLRQDQGFRQŸ∑LFWVRILQWHUHVW

1RW$SSOLFDEOH
8. 
Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following 
format: 
Particulars
FY 2024-25 
FY 2023-24 
Number of days of accounts payables
275
273
9. 
Open-ness of business 
 
Provide details of concentration of purchases and sales with trading houses, dealers and related parties along-with loans 
and advances & investments, with related parties in the following format:
Parameter 
Metrics 
FY 2024-25
FY 2023-24 
Concentration 
of Purchases 
a. 
 Purchases from trading houses as % of total 
purchases 
12%
10%
b. 
 Number of trading houses where purchases are 
made from 
89
90
c. 
 Purchases from top 10 trading houses as % of total 
purchases from trading houses
60%
67.8%
Concentration 
of Sales
a. 
 Sales to dealers / distributors as % of total sales 
59.52%
57.71%
b. 
 Number of dealers / distributors to whom sales are 
made 
292
298
c. 
 Sales to top 10 dealers / distributors as % of total 
sales to dealers / distributors 
51.00%
53.87%
Share of RPTs 
in
a. 
 i) Purchases (Purchases with related parties / Total 
Purchases) 
0.21%
0
b. 
Sales (Sales to related parties / Total Sales)
40.07%
41.85%
c. 
 Loans & advances (Loans & advances given to 
related parties / Total loans & advances) 
96.92%
99.03%
d. 
Investments
 
 (Investments in related parties / Total Investments 
made)
99.63%
93.83%
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
232
Leadership Indicators

$ZDUHQHVVSURJUDPPHVFRQGXFWHGIRUYDOXHFKDLQSDUWQHUVRQDQ\RIWKH3ULQFLSOHVGXULQJWKHŸ∂QDQFLDO\HDU
Total number 
of awareness 
programmes held
Topics / principles covered under the training
%age of value chain partners covered 
(by value of business done with 
such partners) under the awareness 
programmes
05
6XSSOLHUFRGHRIFRQGXFW(PHUJHQF\5HVSRQVHDQG
3UHSDUHGQHVV 3ODQ (+6 3ROLF\ &RQWUDFWRUV (+6
$JUHHPHQW3ODVWLF:DVWH0DQDJHPHQW
100

'RHVWKHHQWLW\KDYHSURFHVVHVLQSODFHWRDYRLGPDQDJHFRQŸ∑LFWRILQWHUHVWVLQYROYLQJPHPEHUVRIWKH%RDUG"<HV1R 
If Yes, provide details of the same. 

<HV ZH KDYH HVWDEOLVKHG UREXVW SURFHVVHV WR PDQDJH FRQŸ∑LFWV RI LQWHUHVW LQYROYLQJ RXU %RDUG PHPEHUV DQG 6HQLRU
0DQDJHPHQW$OO'LUHFWRUVDUHUHTXLUHGWRGLVFORVHWKHLULQWHUHVWVLQRWKHUHQWLWLHVLQFOXGLQJVKDUHKROGLQJVDQQXDOO\RU
XSRQDQ\FKDQJH7KH\DOVRVXEPLWDQDQQXDOGHFODUDWLRQXQGHUWKH&RGHRI&RQGXFWDŸ∏UPLQJWKHLUFRPPLWPHQWWR
DFWLQWKH&RPSDQ\»ÖVEHVWLQWHUHVWVDQGWRDYRLGDQ\SHUVRQDORUEXVLQHVVUHODWLRQVKLSVWKDWFRXOGUHVXOWLQDFRQŸ∑LFW
During Board meetings, Directors abstain from discussions or decisions on matters in which they have an interest. Similarly, 
6HQLRU0DQDJHPHQWLVUHTXLUHGWRSURYLGHDQDQQXDOFRQŸ∂UPDWLRQWKDWWKH\KDYHQRWHQWHUHGLQWRDQ\PDWHULDOŸ∂QDQFLDORU
FRPPHUFLDOWUDQVDFWLRQVWKDWFRXOGFRQŸ∑LFWZLWKWKH&RPSDQ\»ÖVLQWHUHVWV
PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable and safe 
Essential Indicators 

3HUFHQWDJHRI5	'DQGFDSLWDOH[SHQGLWXUHFDSH[LQYHVWPHQWVLQVSHFLŸ∂FWHFKQRORJLHVWRLPSURYHWKHHQYLURQPHQWDO
and social impacts of product and processes to total R&D and capex investments made by the entity, respectively. 
Particulars
FY 2024-25
FY 2023-24
Details of improvements in
environmental social impacts
R&D 
100%
100%
‚Ä¢ 
 Installed the necessary equipment to facilitate the transition from 
High-speed Diesel (HSD) to Low Sulphur Heavy Stock (LSHS).
»ç
,PSOHPHQWHGDYLVXDOPRQLWRULQJPHFKDQLVPIRUWKH(ŸπXHQW7UHDWPHQW
3ODQW(73DWWKH6LNNLPIDFLOLW\IRUVWDWXWRU\DXWKRULW\
‚Ä¢ 
 Installed a solar water heating system at the Nalgarh facility to 
reduce dependency on thermal energy and minimize greenhouse gas 
emissions.
»ç
8SJUDGHGWKH'LUHFW([SDQVLRQ+HDW([FKDQJHURIWKH$LU+DQGOLQJ8QLW
$+8WRD&KLOOHG$LU+DQGOLQJ8QLWDWWKH1DVKLNIDFLOLW\WRHOLPLQDWHWKH
use of refrigerants and coolants, resulting in reduced greenhouse gas 
emissions.
Capex 
0.02%
3.40
2. 
a. 
Does the entity have procedures in place for sustainable sourcing? (Yes/No) 
 
 
Yes
 
b. 
If yes, what percentage of inputs were sourced sustainably? 
 
 
100% of the input materials were sourced sustainably.
3. 
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, 
for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste. 

:HDUHDFWLYHO\HQJDJHGLQWKHPDQXIDFWXUHDQGVDOHRISKDUPDFHXWLFDOSURGXFWVDQGWKHSULPDU\ZDVWHJHQHUDWHGDWWKH
HQGRIOLIHRIWKHVHSURGXFWVLVSODVWLF,QOLQHZLWK([WHQGHG3URGXFHU5HVSRQVLELOLW\(35JXLGHOLQHVZHKDYHLPSOHPHQWHG
robust systems and practices for waste management that comply with pollution control board regulations, ensuring an 
environmentally friendly approach.

7KH SODVWLF ZDVWH UHVXOWLQJ IURP WKH HQGRIOLIH RI RXU SURGXFWV LQFOXGHV ULJLG Ÿ∑H[LEOH DQG PXOWLOD\HUHG SDFNDJLQJ
PDWHULDOV7RPDQDJHWKLVZDVWHHŸµHFWLYHO\ZHKDYHSDUWQHUHGZLWKDWKLUGSDUW\DJHQF\DXWKRUL]HGE\WKHSROOXWLRQFRQWURO
ERDUGWRFROOHFWWKHZDVWHJHQHUDWHGIURPRXURSHUDWLRQVDQGIDFLOLWDWHUHXVHDQGUHF\FOLQJHŸµRUWV7KHUHF\FODEOHSRUWLRQ
Integrated Annual Report FY 2025
233
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
of the waste is transformed into valuable products, such as plastic granules, while the residual waste is co-processed to 
recover energy and ensure safe disposal.

$GGLWLRQDOO\ZHKDYHHVWDEOLVKHGDFHQWUDOL]HGDJUHHPHQWZLWKWKHWKLUGSDUW\DJHQF\IRUWKHUHF\FOLQJRIHOHFWURQLFZDVWH
(e-waste). Battery waste is responsibly managed by being sent to authorized dealers or returned to the supplier for proper 
recycling.
4. 
Whether Extended Producer Responsibility (EPR) is applicable to the entity‚Äôs activities (Yes / No). If yes, whether the 
waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control 
Boards? If not, provide steps taken to address the same. 

<HVWKH([WHQGHG3URGXFHU5HVSRQVLELOLW\(35LVDSSOLFDEOHWRWKH&RPSDQ\DVRXWOLQHGLQWKH3ODVWLF:DVWH0DQDJHPHQW
5XOHVDQGVXEVHTXHQWDPHQGPHQWV:HKDYHREWDLQHG(35DXWKRUL]DWLRQIURPWKH&HQWUDO3ROOXWLRQ&RQWURO%RDUG
&3&%XQGHUERWKWKH%UDQG2ZQHUDQG,PSRUWHUFDWHJRULHV2XUZDVWHFROOHFWLRQSODQDOLJQVZLWKWKH(35WDUJHWVVHWE\
WKH&3&%$GGLWLRQDOO\WKH&RPSDQ\VXEPLWVDQQXDOUHWXUQVWRWKH&3&%DVSDUWRILWV(35FRPSOLDQFHREOLJDWLRQV
Leadership Indicators 
1. 
Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? If yes, provide details in the following format? 
NIC Code
Name of 
Product/
Service
% of total 
turnover 
contributed
Boundary for which the 
Life Cycle Perspective 
/ Assessment was 
conducted
Whether 
conducted by 
independent 
external agency 
(Yes/No)
Results communicated 
in public domain (Yes/ 
No) If yes, provide the 
web-link.
210
Soprobec pMDI
0.10%
Cradle-to-Grave System 
ERXQGDU\LQWKH/&$
Study of Soprobec pMDI
Yes
Results are available but 
not communicated in 
public domain

,IWKHUHDUHDQ\VLJQLŸ∂FDQWVRFLDORUHQYLURQPHQWDOFRQFHUQVDQGRUULVNVDULVLQJIURPSURGXFWLRQRUGLVSRVDORI
\RXUSURGXFWVVHUYLFHVDVLGHQWLŸ∂HGLQWKH/LIH&\FOH3HUVSHFWLYH$VVHVVPHQWV/&$RUWKURXJKDQ\RWKHUPHDQV
EULHŸ∑\GHVFULEHWKHVDPHDORQJZLWKDFWLRQWDNHQWRPLWLJDWHWKHVDPH
Name of Product / Service
Description of the risk / concern
Action Taken
1RW$SSOLFDEOH
3. 
Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing 
industry) or providing services (for service industry). 

1RW$SSOLFDEOH
4. 
Of the products and packaging reclaimed at end of life of products, amount (in metric tons) reused, recycled, and 
safely disposed, as per the following format: 
Particulars
FY 2024-25
FY 2023-24
Re-Used 
Recycled 
Safely 
Disposed 
Re-Used 
Recycled 
Safely 
Disposed 
Plastics (including packaging) 
Nil
1,432*
1,621**
Nil 
2,712
88
(ZDVWH
1$
1$
1$
1$
1$
1$
Hazardous waste 
1$
1$
1$
1$
1$
1$
Other waste 
1$
1$
1$
1$
1$
1$

3RVWFRQVXPHGSODVWLFUHF\FOHGIROORZLQJ(35JXLGHOLQHVDVSHU&3&%

3RVWFRQVXPHGSODVWLFVDIHO\GLVSRVHGE\(QG2IOLIHWUHDWPHQWIROORZLQJ(35JXLGHOLQHVDVSHU&3&%
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
234
5. 
Reclaimed products and their packaging materials (as percentage of products sold) for each product category. 
Indicate product category
Reclaimed products and their packaging materials as % of total 
products sold in respective category
3ODVWLF:DVWH
100%
PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in 
their value chains 
Essential Indicators 
1. 
a. 
Details of measures for the well-being of employees: 
Category 
% of employees covered by 
Total 
(A) 
Health insurance 
Accident 
insurance 
Maternity 
EHQHŸ∂WV
Paternity 
%HQHŸ∂WV
Day Care 
facilities
Number 
(B) 
% (B / 
A) 
Number 
(C)
% (C / 
A)
Number 
(D)
% (D / 
A)
Number 
(E)
% (E / 
A)
Number 
(E)
% (F / 
A)
Permanent employees 
Male 
10,775
10,775
100
10,775
100
1$
1$
5,688
52.8
4,025
37.4
Female 
866
866
100
866
100
866
100
1$
1$
622
71.8
Total 
11,641
11,641
100
11,641
100
866
100
5,688
52.8
4,647
39.9
Other than Permanent employees
Male 
241
133
55.2
101
41.9
1$
1$
37
15.4
5
2.1
Female 
70
64
91.4
40
57.1
70
100
1$
1$
3
4.3
Total 
311
197
63.3
141
45.3
70
100
37
15.4
8
2.6
 
b. 
Details of measures for the well-being of workers: 
Category 
% of workers covered by 
Total 
(A) 
Health insurance 
Accident 
insurance 
Maternity 
EHQHŸ∂WV
Paternity 
%HQHŸ∂WV
Day Care 
Facilities
Number 
(B) 
% (B / 
A)
Number 
(C) 
% (C / 
A) 
Number 
(D) 
% (D / 
A) 
Number 
(E) 
% (E / 
A)
Number 
(E) 
% (F/ 
A)
Permanent workers 
Male 
1,799
1,799
100
1,799
100
1$
1$
1,799
100
1,799
100
Female 
37
37
100
37
100
37
100
1$
1$
37
100
Total 
1,836
1,836
100
1,836
100
37
100
1,799
100
1,836
100
Other than Permanent workers 
Male 
2,610
2,172
83
1,553
60
1$
1$
72
2.8
2,610
100
Female 
225
221
98
107
48
225
100
1$
1$
225
100
Total 
2,835
2,393
84
1,660
59
225
100
72
2.8
2,835
100
 
c. 
Spending on measures towards the well-being of employees and workers (including permanent and other than 
permanent) in the following format.
Particulars
FY 2024-25 
FY 2023-24
Cost incurred on wellbeing measures as a % of total revenue of the 
Company
0.19%
0.17%
Integrated Annual Report FY 2025
235
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview

'HWDLOVRIUHWLUHPHQWEHQHŸ∂WVIRU&XUUHQW)<DQG3UHYLRXV)LQDQFLDO<HDU
%HQHŸ∂WV
FY 2024-25 
FY 2023-24 
No. of 
employees 
covered as 
a % of total 
employees 
No.  of 
workers 
covered as 
a % of total 
workers 
Deducted and 
deposited with 
the authority 
(Y/N/N.A.) 
No. of 
employees 
covered as 
a % of total 
employees 
No. of 
workers 
covered as 
a % of total 
workers 
Deducted and 
deposited with 
the authority 
(Y/N/N.A.) 
PF 
100%
100%
Yes
100%
100%
Yes
Gratuity 
100%
100%
1$
100%
100%
1$
(6,
100%
100%
Yes
100%
100%
Yes
Others ‚Äì please specify 
1$
1$
1$
1$
1$
1$
3. 
Accessibility of workplaces 

$UHWKHSUHPLVHVRŸ∏FHVRIWKHHQWLW\DFFHVVLEOHWRGLŸµHUHQWO\DEOHGHPSOR\HHVDQGZRUNHUVDVSHUWKHUHTXLUHPHQWVRI
WKH5LJKWVRI3HUVRQVZLWK'LVDELOLWLHV$FW",IQRWZKHWKHUDQ\VWHSVDUHEHLQJWDNHQE\WKHHQWLW\LQWKLVUHJDUG

0RVWRIRXUSUHPLVHVDQGRŸ∏FHVKDYHHOHYDWRUVZLGHUDLVOHVDQGFOHDUSDWKZD\VIDFLOLWDWLQJHDV\PRYHPHQWRIGLŸµHUHQWO\
abled employees.
4. 
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, 
provide a web link to the policy. 
 
Glenmark is an equal opportunity employer committed to fostering diversity at the workplace, both in its employees and 
OHDGHUVKLSWHDPLQFOXGLQJGLŸµHUHQWO\DEOHG'LYHUVLW\LQFOXVLYHQHVVDQGUHVSHFWIRUDOOVWHPVIURPRXURUJDQL]DWLRQDOYDOXHV
DQGDUHHVVHQWLDOWRRXUVXFFHVV:HHQVXUHWKHFROODERUDWLYHZRUNHQYLURQPHQWIUHHRIGLVFULPLQDWLRQDQGKDUDVVPHQW
$W*OHQPDUNZHDUHFRPPLWWHGWRPDLQWDLQLQJDQHQYLURQPHQWWKDWFHOHEUDWHVRXUSHRSOH»ÄWKHLUGLŸµHUHQFHVYDOXHVDQG
FRQWULEXWLRQ :H SURYLGH IDLU UHPXQHUDWLRQ HQVXULQJ WKDW WKH FRPSHQVDWLRQ SDFNDJHV DUH HTXLWDEOH FRPSHWLWLYH DQG
FRPPHQVXUDWHZLWKWKHQDWXUHRIWKHZRUNSHUIRUPHGDVZHOODVWKHVNLOOVTXDOLŸ∂FDWLRQVDQGH[SHULHQFHRIWKHLQGLYLGXDO
:HDGKHUHWRDSSOLFDEOHODZVDQGUHJXODWLRQVJRYHUQLQJZDJHVDQGPDLQWDLQWUDQVSDUHQF\LQRXUFRPSHQVDWLRQSDFNDJHV
 
Here is the link to our policy- 
 
KWWSVJOHQPDUNSKDUPDFRPUHVSRQVLELOLW\HTXDORSSRUWXQLW\IRUDOOaWH[W :HDUHFRPPLWWHGWR
the,free%20of%20discrimination%20and%20harassment.
5. 
Return to work and Retention rates of permanent employees and workers that took parental leave. 
FY 2024-25
FY 2023-24
Return to work rate (%)
Retention Rate (%)
Return to work rate (%)
Retention Rate (%)
Male 
100%
84%
100%
90%
Female 
100%
74%
98%
93%
Total 
100%
83%
100%
90%
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
236
6. 
Is there a mechanism available to receive and redress grievances for the following categories of employees and 
workers? If yes, give details of the mechanism in brief. 
Particulars
Yes/No (If Yes, then give details of the mechanism in brief) 
3HUPDQHQW:RUNHUV
*OHQPDUNKDVHVWDEOLVKHGDUREXVW(PSOR\HH*ULHYDQFH3ROLF\DQG(WKLFV3RUWDOWRHQVXUHWKH
VZLIWDQGHŸµHFWLYHUHVROXWLRQRIDQ\FRQFHUQV(PSOR\HHVKDYHDFFHVVWRPXOWLSOHUHSRUWLQJ
FKDQQHOVLQFOXGLQJWKHLUGLUHFWVXSHUYLVRUV+5WKH&RPSOLDQFH2Ÿ∏FHUWKH*ULHYDQFH2Ÿ∏FHU
DQGDQLQGHSHQGHQWO\PDQDJHG(WKLFV/LQH7KLVOLQHDOORZVIRUFRQŸ∂GHQWLDORUDQRQ\PRXV
reporting in various languages.
Grievances can be reported easily via phone or through the dedicated web portal at http://
glenmark.ethicspoint.com, with contact details prominently displayed at the workplace. 
$GGLWLRQDOO\HPSOR\HHVFDQUHDFKRXWYLDHPDLODWJULHYDQFHRŸ∏FHU#JOHQPDUNSKDUPDFRP
for direct communication.
It‚Äôs important to note that Glenmark‚Äôs grievance redressal mechanisms extend to both 
permanent and contractual employees. For those engaged through third-party agencies, 
grievances should be addressed in accordance with the respective agency‚Äôs policies.
Other than Permanent 
:RUNHUV
3HUPDQHQW(PSOR\HHV
Other than Permanent 
(PSOR\HHV
7. 
Membership of employees and workers in association(s) or Unions recognized by the listed entity:
Category 
FY 2024-25
FY 2023-24
Total 
employees 
/ workers in 
respective 
category (A)
No. of 
employees 
/ workers in 
respective 
category, who 
are part of 
association(s) 
or Union (B)
% (B / A
Total 
employees / 
Workers in 
respective 
category (C)
No. of 
employees 
/ workers in 
respective 
category, who 
are part of 
association(s)
or Union (D)
% (D / C)
Male 
10,775
112
1%
10,003
Nil 
1$
Female 
866
130
15%
796
Nil 
1$
Total Permanent 
Employees
11,641
242
2%
10,799
Nil 
N/A
Male 
1,799
350
19%
1,877
359
19%
Female
37
6
16%
60
6
10%
Total Permanent 
Workers 
1,836
356
19%
1,937
365
19%
8. 
Details of training given to employees and workers:
Category 
FY 2024-25
FY 2023-24
Total 
(A) 
 
On Health and 
safety measures 
On Skill 
upgradation
Total 
(D) 
On Health and 
safety measures 
On Skill 
upgradation 
No. 
(B) 
% (B 
/ A) 
No. 
(C) 
% (C / 
A) 
No. 
(E) 
% (E / 
D) 
No. (F) 
% (F / 
D) 
Employees 
Male 
10,775
10,775
100
9,933
92
10,003
10,003
100%
8,506
85%
Female 
866
866
100
866
100
796
796
100%
796
100%
Total 
11,641
11,641
100
10,799
93
10,799
10,799
100%
9,302
86%
Workers 
Male 
1,799
1,799
100
1,799
100
1,877
1,877
100%
1,877 
100%
Female 
37
37
100
37
100
60
60
100%
60
100%
Total 
1,836
1,836
100
1,836
100
1,937
1,937
100%
1,937
100%
Integrated Annual Report FY 2025
237
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
9. 
Details of performance and career development reviews of employees and workers: 
Category
FY 2024-25
FY 2023-24
Total (A)
No. (B)
% (B / A)
Total (C)
No. (D)
% (D/C)
Employees
Male 
9,419
9,419
100
10,003
10,003
100%
Female 
760
760
100
796
796
100%
Total
10,179
10,179
100
10,799
10,799
100%
Workers
Male 
1,329
1,329
100
1,877
1,877
100%
Female 
34
34
100
60
60
100%
Total
1,363
1,363
100
1,937
1,937
100%
10. Health and safety management system: 
 
a. 
Whether an occupational health and safety management system has been implemented by the entity? 
(Yes/ No). If yes, the coverage of such a system? 
 
 
Yes, we have implemented a comprehensive Occupational Health and Safety (OHS) Management System across all 
our facilities in India, which includes 8 manufacturing sites and 3 R&D centers. This system applies to both permanent 
DQGFRQWUDFWXDOHPSOR\HHV6HYHQRIRXUHLJKWPDQXIDFWXULQJVLWHVDUHFHUWLŸ∂HGWR,62XQGHUVFRULQJRXU
commitment to maintaining the highest standards in health and safety.


2XUJRYHUQDQFHIUDPHZRUNULJRURXVO\PRQLWRUVNH\(QYLURQPHQW+HDOWKDQG6DIHW\(+6SHUIRUPDQFHLQGLFDWRUV
ZLWKFRQWLQXRXVRYHUVLJKWWKURXJKERWKLQWHUQDODQGH[WHUQDODXGLWVWRHQVXUHHŸµHFWLYHQHVV:HSURYLGHGHWDLOHG
JXLGHOLQHVRQRQVLWHHPHUJHQF\SUHSDUHGQHVVZRUNSODFHKD]DUGVDQGSUHYHQWLYHPHDVXUHV$GGLWLRQDOO\ZHKDYH
SODFHG FOHDU VDIHW\ VLJQDJH HPHUJHQF\ FRQWDFW LQIRUPDWLRQ HYDFXDWLRQ SODQV Ÿ∂UH DODUPV DQG HQIRUFH SHUVRQDO
SURWHFWLYHHTXLSPHQW33(UHTXLUHPHQWVWRSURDFWLYHO\PDQDJHDQGPLWLJDWH2+6ULVNV
 
b. 
What are the processes used to identify work-related hazards and assess risks on a routine and non-routine 
basis by the entity? 


:RUNSODFHKD]DUGLGHQWLŸ∂FDWLRQLVFDUULHGRXWWKURXJKYDULRXVPHWKRGVLQFOXGLQJ5LVN$VVHVVPHQWV5$+D]DUG
,GHQWLŸ∂FDWLRQ DQG 5LVN $VVHVVPHQW +,5$ SODQW VDIHW\ LQVSHFWLRQV -RE 6DIHW\ $QDO\VLV -6$ DQG 3URFHVV +D]DUG
$QDO\VLV3+$)RUQRQURXWLQHWDVNVZHKDYHHVWDEOLVKHGFRPSUHKHQVLYHV\VWHPVDQGSUDFWLFHVDORQJZLWKLQWHUQDO
JXLGHOLQHVWRHQVXUHFRPSOLDQFHZLWKWKH3HUPLWWR:RUN37:SURFHVVZKLFKLVVXSSRUWHGE\DSULRUULVN
assessment. This process evaluates factors such as the severity and likelihood of potential hazards, the nature of the 
WDVNDQGWKHVXUURXQGLQJHQYLURQPHQW:HVWURQJO\HQFRXUDJHDOOHPSOR\HHVDQGZRUNHUVWRUHSRUWXQVDIHDFWLRQV
conditions, incidents, accidents, or near-miss occurrences through various reporting channels. Once hazards are 
LGHQWLŸ∂HGZHLPSOHPHQWDSSURSULDWHPLWLJDWLRQVWUDWHJLHVWRSUHYHQWZRUNSODFHULVNV


+D]DUG,GHQWLŸ∂FDWLRQ	5LVN$VVHVVPHQW3URFHVV


»ç
'HSDUWPHQWKHDGVLQFROODERUDWLRQZLWKWKH(+6KHDGDUHUHVSRQVLEOHIRULGHQWLI\LQJKD]DUGVDQGDVVHVVLQJWKH
associated risks related to their activities and equipment, and for implementing corrective actions as needed.


»ç
7RDVVHVVULVNOHYHOVZHXVH&URQHU»ÖV»àQRPRJUDP»âWRROZKLFKIDFWRUVLQWKHOLNHOLKRRGRIRFFXUUHQFHIUHTXHQF\
RIH[SRVXUHVHYHULW\SRWHQWLDOKDUPDQGSURSHUW\GDPDJH%DVHGRQWKHLGHQWLŸ∂HGULVNVZHDSSO\DFRPELQDWLRQ
RIHQJLQHHULQJDGPLQLVWUDWLYHDQG33(FRQWUROVWRHOLPLQDWHRUUHGXFHWKHULVNWRDQDFFHSWDEOHOHYHO


»ç
:HLQYROYHHPSOR\HHVDWDOOOHYHOVLQWKHKD]DUGLGHQWLŸ∂FDWLRQSURFHVVDQGDVVLJQWKHPUHVSRQVLELOLW\IRUULVN
mitigation in the workplace. This collaborative approach strengthens our overall safety culture.
 
 
‚Ä¢ 
The site leadership team, which includes plant heads and department heads, undergoes training in the IS14489 
2+6 DXGLWLQJ VWDQGDUG (PSOR\HHV DOVR UHFHLYH ,62  ,QWHUQDO $XGLWRU WUDLQLQJ WR HQKDQFH WKHLU DELOLW\
WRLGHQWLI\KD]DUGVDQGULVNVZLWKLQSODQWSUHPLVHV2+6LQVSHFWLRQVDUHFRQGXFWHGGDLO\E\WKH(+6KHDGLQ
FRRUGLQDWLRQZLWKDUHDRZQHUVZHHNO\E\WKHSODQWKHDGDQGPRQWKO\E\RWKHUGHSDUWPHQWKHDGV7KHŸ∂QGLQJV
IURPWKHVHLQVSHFWLRQVDUHUHYLHZHGHYHU\ZHHNHQGE\WKH*OREDO(+6KHDGDQGWKH*OREDO0DQXIDFWXULQJKHDG
to ensure compliance. On a monthly basis, the same information is presented to the President of Operations for 
further review.
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
238


»ç
:HUHJXODUO\FRQGXFW6DIHW\&KDPSLRQVSURJUDPVDQGKROGPRQWKO\UHYLHZVRI(+6SHUIRUPDQFHPHWULFVDQG
ongoing campaigns to ensure continuous improvement.


»ç
2XULQWHUQDO6WDQGDUG2SHUDWLQJ3URFHGXUH623RQ»à5LVN$VVHVVPHQWDQG6DIH:RUNLQJ3URFHGXUH»âHQVXUHVD
structured approach to risk management.


»ç
$GGLWLRQDOO\ZHFRQGXFWDQQXDODVVHVVPHQWVRI*OREDO6DIHW\3URJUDPVDFURVVDOOVLWHVWRHQVXUHWKHRQJRLQJ
HŸµHFWLYHQHVVRIRXUVDIHW\LQLWLDWLYHV
 
c. 
Whether you have processes for workers to report the work-related hazards and to remove themselves from 
such risks. (Y/N) 
 
 
Yes, we have implemented robust and well-established systems, processes, and practices that enable workers to 
UHSRUW ZRUNUHODWHG KD]DUGV HŸµHFWLYHO\ 'HGLFDWHG VDIHW\ FRPPLWWHHV DUH LQ SODFH WR LGHQWLI\ ZRUNSODFH ULVNV DQG
hazards, recommend and implement corrective actions, support management in achieving safety standards, and 
oversee the investigation and documentation of incidents. To support hazard reporting and allow workers to remove 
themselves from unsafe situations, the following initiatives are in place:
 
 
‚Ä¢ 
Monthly Safety Campaigns are conducted on topics such as electrical safety, emergency equipment, emergency 
SUHSDUHGQHVVPDFKLQHJXDUGLQJWKH3HUPLWWR:RUN37:V\VWHPFKHPLFDOVDIHW\/RFN2XW7DJ2XW	7U\2XW
/272KDQGDQGŸ∂QJHUSURWHFWLRQURDGVDIHW\DQGWUDŸ∏FPDQDJHPHQWVDIHEHKDYLRUDQGZRUNLQJDWKHLJKW
These campaigns aim to reduce incident rates and enhance awareness among all employees and workers.
 
 
‚Ä¢ 
Through the Safety Champion Programme, employees and workers who identify unsafe acts and unsafe 
FRQGLWLRQV8$	8&UHSRUWWKHPYLDWKHRQOLQHSRUWDORUFRQGXFW7RRO%R[7DONV7%7DUHUHFRJQL]HGDQG
rewarded for their contributions to workplace safety.
 
 
‚Ä¢ 
Global Safety Programs have been implemented across all Glenmark facilities, with regular assessments 
FRQGXFWHG7KHVHSURJUDPVLQFOXGH&RQWUDFWRU6DIHW\&KHPLFDO6DIHW\:RUNLQJDW+HLJKW6DIHW\/RFN2XW7DJ
2XW6\VWHP6DIHW\(OHFWULFDO6DIHW\&RQŸ∂QHG6SDFH6DIHW\0DFKLQH*XDUGLQJ6DIHW\(PHUJHQF\3UHSDUHGQHVV	
5HVSRQVH0DQDJHPHQWRI&KDQJH&RQWURO3HUVRQDO3URWHFWLYH(TXLSPHQW2FFXSDWLRQDO+HDOWK0DQDJHPHQW
,QGXVWULDO+\JLHQH7UDŸ∏F0DQDJHPHQW(UJRQRPLFV3URFHVV6DIHW\DQG/LIWLQJ7RROV	7DFNOHV6HYHUDORIWKHVH
programs have been digitalized through the launch of e-learning modules on topics such as Chemical Safety, 
0DFKLQH*XDUGLQJ&RQWUDFWRU6DIHW\/RFN2XW7DJ2XWDQG&RQŸ∂QHG6SDFH(QWU\WRHQVXUHHDVHRIDFFHVVDQG
HŸµHFWLYHOHDUQLQJ


»ç
0RQWKO\ (+6 3HUIRUPDQFH $VVHVVPHQWV DUH FRQGXFWHG EDVHG RQ YDULRXV (QYLURQPHQWDO +HDOWK DQG 6DIHW\
(+6LQGLFDWRUVDQGKLJKSHUIRUPLQJLQGLYLGXDOVDUHUHFRJQL]HGDV»à%HVW(+63HUIRUPHUV»â


»ç
%HKDYLRU%DVHG6DIHW\6XUYH\VKDYHEHHQFDUULHGRXWDWVHOHFWORFDWLRQVWKURXJKLQWHUYLHZVIRFXVHGRQ(+6
parameters, targeting top and middle management as well as value chain partners.


»ç
7KH%ULWLVK6DIHW\&RXQFLOFRQGXFWHGDJDSDXGLWDWWKH&KKDWUDSDWL6DPEKDML1DJDU$XUDQJDEDGVLWHIXUWKHU
strengthening our safety evaluation processes.British Safety Council has conducted gap audit and hand-holding 
VHVVLRQVIRU&KKDWUDSDWL6DPEKDML1DJDU$XUDQJDEDGVLWH


»ç
&RQGXFWHGWUDLQLQJRQ»à&RQWURORI6XEVWDQFHV+D]DUGRXVWR+HDOWK»â&26++WR6LWH(+6OHDGV
 
 
‚Ä¢ 
Conducted site inspection & interaction with Senior Leadership team at Baddi & Indore site to design safety 
leadership program through external agency.
 
 
‚Ä¢ 
Conducted Safety leadership workshop at Baddi & Indore for developing safety culture at site


»ç
&RQGXFWHG:HOOEHLQJZRUNVKRSDW+HDG2Ÿ∏FHDQG&KKDWUDSDWL6DPEKDMLQDJDUVLWHIRU6HQLRU0DQDJHPHQW


»ç
$1HDU0LVVDQG+D]DUG0DQDJHPHQW2QOLQH3RUWDOKDVEHHQHVWDEOLVKHGHQDEOLQJHPSOR\HHVWRUHSRUWQHDU
PLVVLQFLGHQWVDQGKD]DUGV7KLVV\VWHPHQVXUHVWLPHO\ULVNHYDOXDWLRQDQGFRUUHFWLYHDFWLRQV$QLQWHUQDO623
WLWOHG »à5HSRUWLQJ RI 1HDU0LVV 	 +D]DUG DQG ,PSOHPHQWDWLRQ RI &RUUHFWLYH $FWLRQ 7KURXJK 2QOLQH 3RUWDO»â LV
available on the company intranet to guide the process.
 
 
‚Ä¢ 
Training Programs on incident investigation and root cause analysis have been delivered by external health and 
safety experts to enhance internal capability.
Integrated Annual Report FY 2025
239
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
 
 
‚Ä¢ 
OHS Inspections are regularly carried out at sites by Department Heads and Site Leaders to identify hazards early 
and implement corrective measures before incidents occur.
 
 
‚Ä¢ 
Safety Committee Meetings serve as an essential platform for employees to raise safety concerns, which are then 
discussed and resolved to mitigate associated risks.
 
d. 
Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? 
(Yes/ No) 
 
 
Yes, we regularly organize medical camps and health screenings aimed at detecting non-work-related health 
conditions and ensuring timely treatment. To further support the overall well-being of our employees and workers, 
ZHDOVRFRQGXFWYDULRXVZHOOQHVVLQLWLDWLYHVLQFOXGLQJVHVVLRQVRQQXWULWLRQŸ∂WQHVVDFWLYLWLHV\RJDSURJUDPVDQG
health and safety awareness training
11. Details of safety related incidents, in the following format: 
Safety Incident/Number 
Category 
FY 2024-25
FY 2023-24
Lost Time Injury Frequency Rate (LTIFR) (per one million-
person hours worked) 
(PSOR\HHV
0.22
0.08
:RUNHUV
0.48 
0
Total recordable work-related injuries 
(PSOR\HHV
3
3
:RUNHUV
4
1
No. of fatalities 
(PSOR\HHV
0
0
:RUNHUV
0
0
High 
consequence 
work-related 
injury 
or 
ill-health 
(excluding fatalities) 
(PSOR\HHV
0
0
:RUNHUV
0
0
12. Describe the measures taken by the entity to ensure a safe and healthy workplace 

:HDUHFRPPLWWHGWRHQVXULQJZRUNSODFHVDIHW\E\HPEHGGLQJD»à6DIHW\LVHYHU\RQH»ÖVGXW\»âPLQGVHWDFURVVDOOOHYHOVRIWKH
RUJDQL]DWLRQIURPPDQDJHPHQWWRRSHUDWLRQDOHPSOR\HHV2XUPDQXIDFWXULQJVLWHVDUH,62FHUWLŸ∂HGIROORZLQJ
WKH»à3ODQ'R&KHFN$FW»âIUDPHZRUNWRPDQDJH2+6ULVNVVXFKDVIDOOVŸ∂UHHTXLSPHQWLQMXULHVDQGWR[LFH[SRVXUH:H
HPSOR\UREXVWPHFKDQLVPVOLNH*OREDO6DIHW\3URJUDPVWKH:RUN3HUPLW6\VWHPUHJXODU2+6LQVSHFWLRQVUHDOWLPH1HDU
Miss & Hazard reporting, and emergency response drills to continuously enhance safety standards. This collaborative 
approach has cultivated a strong, adaptable safety culture that drives ongoing improvements in employee health and 
safety.
13. Number of Complaints on the following made by employees and workers:
FY 2024- 25
FY 2023-24
Filed during 
the year 
 
Pending 
resolution at 
the end of year 
Remarks
Filed during 
the year
Pending 
resolution at 
the end of year
Remarks
:RUNLQJ&RQGLWLRQV
Nil
1$
1$
Nil
1$
1$
Health & Safety 
Nil
1$
1$
Nil
1$
1$
14. Assessments for the year: 
Particulars
RI\RXUSODQWVDQGRŸ∏FHVWKDWZHUHDVVHVVHGE\HQWLW\RU
statutory authorities or third parties) 
Health and safety practices 
100%
:RUNLQJ&RQGLWLRQV
100%
15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on 
VLJQLŸ∂FDQWULVNVFRQFHUQVDULVLQJIURPDVVHVVPHQWVRIKHDOWK	VDIHW\SUDFWLFHVDQGZRUNLQJFRQGLWLRQV

:H FRQGXFW UHJXODU LQWHUQDO VDIHW\ DXGLWV DFURVV DOO RXU IDFLOLWLHV LPSOHPHQWLQJ FRUUHFWLYH DFWLRQV EDVHG RQ WKH DXGLW
Ÿ∂QGLQJV6HYHQRIRXUHLJKWPDQXIDFWXULQJVLWHVKROG,62FHUWLŸ∂FDWLRQXQGHUVFRULQJRXUGHGLFDWLRQWRVDIHW\
H[FHOOHQFH7RHQVXUHSUHSDUHGQHVVZHRUJDQL]HUHJXODUPRFNGULOOVDQGVDIHW\WUDLQLQJIRUDOOHPSOR\HHVDQGZRUNHUV:H
KDYHHVWDEOLVKHGDQHPHUJHQF\UHVSRQVHWHDPWUDLQHGWRKDQGOHDQ\FULVLVZLWKRQJRLQJWUDLQLQJLQŸ∂UVWDLGŸ∂UHŸ∂JKWLQJ
and other critical safety procedures. Furthermore, we host awareness sessions on safety topics to continually engage and 
educate our workforce, ensuring a strong culture of safety at every level.
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
240
Leadership Indicators 
1. 
Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) 
(B) Workers (Y/N). 

<HV:HKDYHOLIHLQVXUDQFHSROLFLHVFRYHULQJDOOHPSOR\HHVDQGZRUNHUVRI*OHQPDUN3KDUPDFHXWLFDOV/LPLWHGZKLFK
LQFOXGH*URXS7HUP/LIH,QVXUDQFH7HUPOLIHLQOLHXRI('/,DQG*URXS3HUVRQDO$FFLGHQW
2. 
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by 
the value chain partners. 

:HHQVXUHWKDWVWDWXWRU\GXHVDVDSSOLFDEOHWRWKHWUDQVDFWLRQVZLWKLQLWVUHPLWDUHGHGXFWHGDQGGHSRVLWHGLQDFFRUGDQFH
with the applicable regulations. The Company also expects its value chain partners to uphold business responsibility 
principles and values of transparency and accountability by timely payment of statutory dues.

3URYLGHWKHQXPEHURIHPSOR\HHVZRUNHUVKDYLQJVXŸµHUHGKLJKFRQVHTXHQFHZRUNUHODWHGLQMXU\LOOKHDOWK
fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment: 
7RWDOQRRIDŸµHFWHGHPSOR\HHV
workers
No. of employees/workers that are 
rehabilitated and placed in suitable 
employment or whose family 
members have been placed in suitable 
employment
FY 2024-25
FY2023-24
FY 2024-25
FY 2023-24
:RUNHUV
Nil
Nil
Nil
Nil
(PSOR\HHV
Nil
Nil
Nil
Nil
4. 
Does the entity provide transition assistance programs to facilitate continued employability and the management 
of career endings resulting from retirement or termination of employment? (Yes/ No) 
 
No
5. 
Details on assessment of value chain partners: 
% of value chain partners (by value of business done with 
such partners) that were assessed
Health and Safety Practices
100%
Value Chain Partners 
100%

3URYLGHGHWDLOVRIDQ\FRUUHFWLYHDFWLRQVWDNHQRUXQGHUZD\WRDGGUHVVVLJQLŸ∂FDQWULVNVFRQFHUQVDULVLQJIURP
assessments of health and safety practices and working conditions of value chain partners.

1RW$SSOLFDEOH
PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders 
Essential Indicators 
1. 
Describe the processes for identifying key stakeholder groups of the entity. 

7KHSURFHVVRILGHQWLI\LQJDQGHQJDJLQJZLWKVWDNHKROGHUVDW*OHQPDUNIROORZVIRXUNH\VWHSVVWDNHKROGHULGHQWLŸ∂FDWLRQ
review, communication channels, and engagement frequency.

»ç
6WDNHKROGHU ,GHQWLŸ∂FDWLRQ :H LGHQWLI\ UHOHYDQW VWDNHKROGHUV EDVHG RQ IDFWRUV OLNH LPSDFW LQWHUHVW OHJLWLPDF\
LQŸ∑XHQFHDQGFULWLFDOLW\(DFKVWDNHKROGHUJURXSKDVGLVWLQFWFRQFHUQVQHHGVH[SHFWDWLRQVDQGSULRULWLHV

»ç
5HYLHZ3URFHVV:HSHULRGLFDOO\UHYLHZDQGXSGDWHWKHVWDNHKROGHULGHQWLŸ∂FDWLRQSURFHVVWRUHŸ∑HFWWKHLUIHHGEDFNDQG
DQ\VLJQLŸ∂FDQWRSHUDWLRQDORUVWUDWHJLFFKDQJHVZLWKLQWKHRUJDQL]DWLRQ
 
‚Ä¢ 
Communication Channels: The communication channels we use are tailored to each stakeholder group, considering 
their type, accessibility, and size. These include one-on-one meetings, virtual and in-person sessions, site visits, 
surveys, feedback, and focused group discussions.
Integrated Annual Report FY 2025
241
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview

»ç
)UHTXHQF\RI(QJDJHPHQW7KHIUHTXHQF\RIHQJDJHPHQWZLWKHDFKVWDNHKROGHUJURXSLVGHWHUPLQHGE\WKHLUVSHFLŸ∂F
QHHGVDVLGHQWLŸ∂HGWKURXJKWKHVWDNHKROGHUUHYLHZSURFHVVHQVXULQJHŸµHFWLYHDQGUHOHYDQWFRPPXQLFDWLRQ

/LVWVWDNHKROGHUJURXSVLGHQWLŸ∂HGDVNH\IRU\RXUHQWLW\DQGWKHIUHTXHQF\RIHQJDJHPHQWZLWKHDFKVWDNHKROGHU
group. 

3OHDVHUHIHUWKH,QWHJUDWHG$QQXDO5HSRUWIRUWKH)<
Leadership Indicators 
1. 
Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social 
topics or if consultation is delegated, how is feedback from such consultations provided to the Board. 

:H HQJDJH ZLWK UHOHYDQW VWDNHKROGHUV DV QHHGHG IROORZLQJ RXU VWDNHKROGHU HQJDJHPHQW SODQ WR JDWKHU LQVLJKWV RQ
economic, environmental, and social matters regularly. Feedback is collected through various channels, including physical 
meetings, virtual calls, emails, surveys, and phone conversations. This input is periodically presented to the Board to inform 
decision-making on key sustainability issues.

:KHWKHUVWDNHKROGHUFRQVXOWDWLRQLVXVHGWRVXSSRUWWKHLGHQWLŸ∂FDWLRQDQGPDQDJHPHQWRIHQYLURQPHQWDODQG
social topics (Yes / No). If so, provide details of instances as to how the input received from stakeholders on these 
topics was incorporated into policies and activities of the entity. 

:HKDYHLGHQWLŸ∂HGNH\(QYLURQPHQW6RFLDODQG*RYHUQDQFH(6*LVVXHVWKURXJKDWKRURXJKPDWHULDOLW\DVVHVVPHQW7KLV
process involved surveys of our employees and senior management, an analysis of relevant sustainability frameworks, and 
EHQFKPDUNLQJDJDLQVWLQGXVWU\SHHUV:HJDWKHUHGYDOXDEOHVWDNHKROGHULQSXWWKURXJKWDUJHWHGTXHVWLRQQDLUHVDOORZLQJ
XVWRSULRULWL]HWKHPRVWFULWLFDO(6*WRSLFV2XUEXVLQHVVVWUDWHJ\JRDOVDQGWDUJHWVDUHVWUDWHJLFDOO\DOLJQHGZLWKWKHVH
material issues to ensure a focused and impactful approach.
3. 
Provide details of instances of engagement with, and actions taken to address the concerns of vulnerable/ 
marginalized stakeholder groups. 

:HDUHFRPPLWWHGWRVXSSRUWLQJDQGHPSRZHULQJVRFLHW\»ÖVXQGHUUHSUHVHQWHGDQGGLVDGYDQWDJHGJURXSV5HFRJQL]LQJ
WKHXQLTXHFKDOOHQJHVIDFHGE\ZRPHQGLŸµHUHQWO\DEOHGLQGLYLGXDOVDQGRWKHUYXOQHUDEOHSRSXODWLRQV*3/SODFHVVSHFLDO
emphasis on addressing their needs. Our CSR initiatives focus on critical areas such as education, health and hygiene, 
HQYLURQPHQWDO VXVWDLQDELOLW\ DQG WKH ZHOIDUH RI ZRPHQ DQG FKLOGUHQ 7KHVH HŸµRUWV DUH VSHFLŸ∂FDOO\ GHVLJQHG WR XSOLIW
XQGHUSULYLOHJHGPDUJLQDOL]HGDQGYXOQHUDEOHFRPPXQLWLHV7KURXJKRXWWKHUHSRUWLQJSHULRGQRVLJQLŸ∂FDQWLVVXHVZHUH
UHSRUWHGE\WKHVHVWDNHKROGHUJURXSVUHŸ∑HFWLQJWKHHŸµHFWLYHQHVVRIRXULQFOXVLYHDSSURDFK
PRINCIPLE 5 Businesses should respect and promote human rights 
Essential Indicators 
1. 
Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the 
following format: 
Category 
FY 2024-25 
FY 2023-24
Total (A) *
No. of employees 
/ workers 
covered (B) 
% (B / A) 
Total (C) 
No. of employees‚Äô 
workers covered 
(D) 
% (D / C) 
Employees 
Permanent 
11,641
5,594
48%
10,799
10,799
100%
Other than permanent 
311
Nil
1$
120 
Nil 
1$
Total Employees 
11,952
5,594
47%
10,919
10,799
98.90%
Workers 
Permanent 
1,836
1,836
100%
1,937
1,937
100%
Other than permanent 
2,835
Nil
1$
3,431
Nil 
1$
Total Workers 
4,671
1,836
39.3
5,368
1,937
36.08%
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
242
2. 
Details of minimum wages paid to employees and workers, in the following format: 
Category 
FY 2024-25
FY 2023-24 
Total 
(A) 
 
Equal to 
Minimum 
Wage 
More than 
Minimum 
Wage 
Total 
(D) 
Equal to 
Minimum 
Wage 
More than 
Minimum 
Wage 
No. 
(B) 
% (B / 
A) 
No. 
(C) 
% (C / 
A) 
No. 
(E) 
% (E / 
D) 
No. 
(F) 
% (F / 
D) 
Employees 
Permanent 
Male 
10,775
220
2%
10,555
98%
10,003
163
1.63%
9,840
98.37%
Female 
866
32
4%
834
96%
796
26
3.27%
770
96.70%
Other than Permanent 
Male 
241
132
55%
109
45%
66
64
96.97%
2
3.03%
Female 
70
18
26%
52
74%
54
52
96.20%
2
3.70%
Workers 
Permanent 
Male 
1,799
373
21%
1,426
79%
1,877
310
16.52%
1,567
83.48%
Female 
37
23
62%
14
38%
60
26
43.3%
34
56.67%
Other than Permanent 
Male 
2,610
984
38%
1,626
62%
3,029
1,059
34.96%
1,970
65.04%
Female 
225
99
44%
126
56%
402
126
31.34%
276
68.66%
3. 
Details of remuneration/ salary/ wages 
 
a. 
Median remuneration/ wages
Category 
Male 
Female
Number
 
Median remuneration/ 
salary/ wages of 
respective category
Number
Median remuneration/ 
salary/ wages of 
respective category
Board of Directors (BoD)
2
ÿ©
1
ÿ©
Key Managerial Personnel
1
ÿ©
0
(PSOR\HHVRWKHUWKDQ%R'DQG.03
10772
ÿ©
865 
ÿ©
:RUNHUV
1799
ÿ©
37 
ÿ©
 
 
Note: 



:HKDYHRQH.H\0DQDJHULDO3HUVRQQHO.03ZKHUHLQDOORXU%RDUGRI'LUHFWRUV%R'VDOVRVHUYHDV.03V



7KHVLWWLQJIHHVSDLGWR1RQ([HFXWLYH'LUHFWRUVDUHH[FOXGHGIURPWKHFDOFXODWLRQRIPHGLDQUHPXQHUDWLRQ
 
b. 
Gross wages paid to females as a % of total wages paid by the entity, in the following format:
Particulars
FY 2024-25
FY 2023-24
Gross wages paid to females as a % of total wages
9.40%
9.45%
4. 
Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused 
or contributed to by the business? (Yes/No) 
 
Yes
Integrated Annual Report FY 2025
243
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
5. 
Describe the internal mechanisms in place to redress grievances related to human rights issues. 
 
The Company has established a grievance redressal mechanism to address any complaints related to human rights 
YLRODWLRQV$OOHPSOR\HHVDQGZRUNHUVDUHHQFRXUDJHGWRUHSRUWFRQFHUQVLQYROYLQJLQMXVWLFHXQIDLUWUHDWPHQWFULWLFLVP
RUYLRODWLRQVRIGLJQLW\$Q\EUHDFKRIKXPDQULJKWVDVRXWOLQHGLQ*OHQPDUN»ÖV+XPDQ5LJKWV3ROLF\6WDWHPHQWVKRXOG
EHUHSRUWHGWRWKHORFDO+5GHSDUWPHQWRUWKH*OHQPDUNOHJDOWHDPDWJOREDOFRPSOLDQFH#JOHQPDUNSKDUPDFRP:HDUH
committed to promptly investigating and addressing these concerns, ensuring appropriate action is taken in response to 
DQ\FRQŸ∂UPHGYLRODWLRQV
 
The Glenmark Human Rights Policy Statement is available at: https://glenmark.b-cdn.net/gpl_pdfs/about_us/Human%20
5LJKWV3ROLF\B$SGI
6. 
Number of Complaints on the following made by employees and workers:
Particulars
FY 2024-25 
FY 2023-24 
Filed
Pending
Remarks
Filed
Pending
Remarks
Sexual Harassment
4
 0
1$
5
Nil
1$
Discrimination at workplace
Nil
Nil
1$
Nil
Nil
1$
Child Labor
Nil
Nil
1$
Nil
Nil
1$
Forced labor/ Involuntary labor
Nil
Nil
1$
Nil
Nil
1$
:DJHV
Nil
Nil
1$
Nil
Nil
1$
Other human rights related issues
19
3
1$
18
3
1$

&RPSODLQWVŸ∂OHGXQGHUWKH6H[XDO+DUDVVPHQWRI:RPHQDW:RUNSODFH3UHYHQWLRQ3URKLELWLRQDQG5HGUHVVDO$FW
2013, in the following format: 
Particulars 
FY 2024-25
FY 2023-24
7RWDO &RPSODLQWV UHSRUWHG XQGHU 6H[XDO +DUDVVPHQW RI :RPHQ DW
:RUNSODFH3UHYHQWLRQ3URKLELWLRQDQG5HGUHVVDO$FW326+
4
5
Complaints on POSH as a % of female employees / workers 
0.44%
0.58%
Complaints on POSH upheld 
4
5
8. 
Mechanisms to prevent adverse consequences to the complaint in discrimination and harassment cases. 

:HKDYHHVWDEOLVKHGUREXVWPHFKDQLVPVWRSURWHFWFRPSODLQWVLQFDVHVRIGLVFULPLQDWLRQDQGKDUDVVPHQW

»ç
,PSOHPHQWHGDQ(PSOR\HH*ULHYDQFH5HGUHVVDO3ROLF\DQGD3UHYHQWLRQRI6H[XDO+DUDVVPHQW326+3ROLF\VSHFLŸ∂FDOO\
to address such issues.

»ç
(PSOR\HHVDUHHQFRXUDJHGWRUDLVHFRQFHUQVIUHHO\DQGZLWKRXWIHDURIUHWDOLDWLRQ:HVWULFWO\SURKLELWDQ\IRUPRI
negative treatment towards individuals who report issues in good faith.

»ç
$Q\SHUVRQIRXQGUHWDOLDWLQJDJDLQVWDFRPSODLQDQWZLOOIDFHFRUUHFWLYHPHDVXUHVZKLFKPD\LQFOXGHGLVFLSOLQDU\
actions up to and including termination of employment or contract.
 
‚Ä¢ 
In line with Glenmark‚Äôs Human Rights Policy Statement, no reprisal or retaliatory action will be taken against employees 
who report human rights violations.

»ç
$OOUHSRUWVRIGLVFULPLQDWLRQDQGKDUDVVPHQWDUHKDQGOHGZLWKVWULFWFRQŸ∂GHQWLDOLW\DQGUHVROYHGSURPSWO\

»ç
$GGLWLRQDOO\ZHUHJXODUO\SURYLGHFRPSUHKHQVLYHWUDLQLQJRQKXPDQULJKWVDQGSUHYHQWLRQRIVH[XDOKDUDVVPHQWWR
all employees and workers.
9. 
Do human rights requirements form part of your business agreements and contracts? (Yes/No)
 
Yes. Human rights requirements are an integral part of our business agreements and contracts. Our Supplier Code of 
&RQGXFWPDQGDWHVWKDWDOOVXSSOLHUVSURKLELWFKLOGODERUIRUFHGODERUKXPDQWUDŸ∏FNLQJDQGPRGHUQGD\VODYHU\,WDOVR
requires suppliers to avoid discrimination based on race, color, gender, age, nationality, religion, sexual orientation, or 
PDULWDOVWDWXVZLWKFRPSOLDQFHPRQLWRUHGWKURXJKSHULRGLFDXGLWV$GGLWLRQDOO\VXSSOLHUVPXVWFRPSO\ZLWKDOODSSOLFDEOH
ODZVDQGLQGXVWU\VWDQGDUGVUHODWHGWRZDJHVRYHUWLPHDQGPDQGDWHGEHQHŸ∂WV
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
244
10. Assessments for the year: 
RI\RXUSODQWVDQGRŸ∏FHVWKDWZHUHDVVHVVHGE\HQWLW\RUVWDWXWRU\DXWKRULWLHVRUWKLUGSDUWLHV
Child labour
100%
Forced/involuntary labour
100%
Sexual harassment
100%
Discrimination at workplace
100%
:DJHV
100%
:RUNLQJ&RQGLWLRQV
100%
Health and Safety 
100%
 3URYLGHGHWDLOVRIDQ\FRUUHFWLYHDFWLRQVWDNHQRUXQGHUZD\WRDGGUHVVVLJQLŸ∂FDQWULVNVFRQFHUQVDULVLQJIURPWKH
assessments at Question 10 above. 

1RVLJQLŸ∂FDQWULVNVFRQFHUQVLGHQWLŸ∂HGGXULQJWKHDVVHVVPHQW
Leadership Indicators 

'HWDLOV RI D EXVLQHVV SURFHVV EHLQJ PRGLŸ∂HG  LQWURGXFHG EHFDXVH RI DGGUHVVLQJ KXPDQ ULJKWV JULHYDQFHV
complaints. 

:HURXWLQHO\UHYLHZRXUEXVLQHVVSURFHVVHVWRHQVXUHWKH\DOLJQZLWKRXUFRPPLWPHQWWRKXPDQULJKWVSDUWLFXODUO\LQ
DGGUHVVLQJJULHYDQFHVDQGFRPSODLQWV2XUFXUUHQW+XPDQ5LJKWV3ROLF\HŸµHFWLYHO\LGHQWLŸ∂HVDGGUHVVHVDQGPLWLJDWHVDOO
known risks related to human rights.
2. 
Details of the scope and coverage of any Human rights conducted due diligence.

:HKDYHHVWDEOLVKHGDFRPSUHKHQVLYHKXPDQULJKWVGXHGLOLJHQFHSURFHVVWRSURDFWLYHO\LGHQWLI\DQGDGGUHVVSRWHQWLDO
violations within our operations, including child labor, forced labor, discrimination, harassment, and restrictions on freedom 
of association. Our core values serve as the foundation of a responsible and esteemed organization, guiding us to conduct 
EXVLQHVVZLWKXWPRVWUHVSHFWIRUWKHGLJQLW\DQGIXQGDPHQWDOULJKWVRIRXUZRUNIRUFH:HHQVXUHVWULFWFRPSOLDQFHZLWK
all applicable statutory laws, human rights directives, and internal codes of conduct, which are rigorously reviewed on a 
quarterly basis. 
 
During the current reporting period, we assessed 100% of our operations for adherence to human rights standards and 
KDYH SURYLGHG VSHFLDOL]HG WUDLQLQJ RQ UHOHYDQW ODZV DQG SUDFWLFHV WR DOO HPSOR\HHV :H DUH FRPPLWWHG WR DOLJQLQJ RXU
business practices with the principles set forth in the United Nations Universal Declaration of Human Rights, and we expect 
all individuals working for or on behalf of Glenmark to uphold these principles. Our Human Rights Policy underscores 
respect for all human rights, the elimination of discriminatory practices, the promotion of diversity, the prohibition of child 
and forced labor, and the provision of a safe, healthy, and transparent working environment where open communication is 
encouraged and respected globally.

,VWKHSUHPLVHRŸ∏FHRIWKHHQWLW\DFFHVVLEOHWRGLŸµHUHQWO\DEOHGYLVLWRUVDVSHUWKHUHTXLUHPHQWVRIWKH5LJKWVRI
Persons with Disabilities Act, 2016? 

<HVWKHSUHPLVHVDQGRŸ∏FHVRIWKH&RPSDQ\DUHDFFHVVLEOHWRGLŸµHUHQWO\DEOHGYLVLWRUVDVSHUWKHUHTXLUHPHQWVRIWKH
5LJKWVRI3HUVRQVZLWK'LVDELOLWLHV$FW7KHRŸ∏FHVKDYHQHFHVVDU\LQIUDVWUXFWXUHDUUDQJHPHQWVIDFLOLWDWLQJHDV\DFFHVV
WRGLŸµHUHQWO\DEOHGYLVLWRUV
4. 
Details on assessment of value chain partners: 
% of value chain partners (by value of business done with such partners) that were assessed
Child labour
100%
Forced/involuntary labour
100%
Sexual harassment
100%
Discrimination at workplace
100%
:DJHV
100%
:RUNLQJ&RQGLWLRQV
100%
Health and Safety 
100%
Integrated Annual Report FY 2025
245
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview

3URYLGHGHWDLOVRIDQ\FRUUHFWLYHDFWLRQVWDNHQRUXQGHUZD\WRDGGUHVVVLJQLŸ∂FDQWULVNVFRQFHUQVDULVLQJIURPWKH
assessments at Question 4 above. 

$WRXU&RPSDQ\ZHSODFHDVWURQJHPSKDVLVRQZRUNSODFHVDIHW\:HFRQGXFWLQWHUQDODXGLWVRQDUHJXODUEDVLVWRPRQLWRU
VDIHW\UHODWHGSDUDPHWHUVDFURVVRXUSUHPLVHVDQGZHWDNHFRUUHFWLYHDFWLRQVSURPSWO\EDVHGRQWKHŸ∂QGLQJV&XUUHQWO\
RXWRIRXUPDQXIDFWXULQJIDFLOLWLHVDUH,62FHUWLŸ∂HGDQGZHXQGHUJRWKLUGSDUW\DXGLWVHYHU\\HDUDVSDUWRI
PDLQWDLQLQJWKLVFHUWLŸ∂FDWLRQ

:HDOVRFRQGXFWUHJXODUPRFNGULOOVDQGVDIHW\WUDLQLQJVHVVLRQVWRHQVXUHRXUHPSOR\HHVDQGZRUNHUVDUHZHOOSUHSDUHG
IRUDQ\HPHUJHQFLHV:H»ÖYHIRUPHGDQ(PHUJHQF\5HVSRQVH7HDP(57PDGHXSRIWUDLQHGHPSOR\HHVZKRDUHHTXLSSHG
WRKDQGOHHPHUJHQFLHVRQVLWH7KH\UHFHLYHRQJRLQJWUDLQLQJLQDUHDVVXFKDVŸ∂UVWDLGŸ∂UHŸ∂JKWLQJDQGRWKHUHVVHQWLDO
emergency procedures.
 
In addition, we organize periodic awareness sessions to educate our teams on key safety practices and relevant safety 
WRSLFV7KHVHHŸµRUWVKHOSXVEXLOGDVWURQJVDIHW\FXOWXUHDFURVVDOORXUIDFLOLWLHVDQGHQVXUHWKHZHOOEHLQJRIHYHU\RQHRQ
site.
35,1&,3/(%XVLQHVVHVVKRXOGUHVSHFWDQGPDNHHŸµRUWVWRSURWHFWDQGUHVWRUHWKHHQYLURQPHQW
(VVHQWLDO,QGLFDWRUV
1. 
Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format: 
Parameter 
FY 2024-25
FY 2023-24
From renewable sources 
7RWDOHOHFWULFLW\FRQVXPSWLRQ$*-
16,602
18,481
7RWDOIXHOFRQVXPSWLRQ%*-
22,097
8,958
(QHUJ\FRQVXPSWLRQWKURXJKRWKHUVRXUFHV&*-
Nil
Nil
Total energy consumed from renewable sources (A+B+C) (GJ)
38,699
27,439
From non-renewable sources 
7RWDOHOHFWULFLW\FRQVXPSWLRQ'*-
3,77,263
3,50,055
7RWDOIXHOFRQVXPSWLRQ(*-
1,54,524
1,36,968
(QHUJ\FRQVXPSWLRQWKURXJKRWKHUVRXUFHV)*-
Nil
Nil
7RWDOHQHUJ\FRQVXPHGIURPQRQUHQHZDEOHVRXUFHV'()*-
5,31,787
4,87,023
Total energy consumed (A+B+C+D+E+F) (GJ)
5,70,486
5,14,462
(QHUJ\ LQWHQVLW\ SHU UXSHH RI WXUQRYHU 7RWDO HQHUJ\ FRQVXPHG LQ *- 
Revenue from operations in INR Crores)
62
65
(QHUJ\ LQWHQVLW\ SHU UXSHH RI WXUQRYHU DGMXVWHG IRU 3XUFKDVLQJ 3RZHU
3DULW\333*-
7RWDOHQHUJ\FRQVXPHGLQ*-5HYHQXHIURPRSHUDWLRQVDGMXVWHGIRU
PPP in USD terms
1,277
1,460
(QHUJ\LQWHQVLW\LQWHUPVRISK\VLFDORXWSXW*-07RI3URGXFWLRQ
38
34
 
Note:,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1 
If yes, name of the external agency. 
 
Yes, reasonable level of assurance for BRSR core indicators has been carried out by an external agency for FY2024-25. The 
H[WHUQDODJHQF\LV'19%XVLQHVV$VVXUDQFH,QGLD3ULYDWH/LPLWHG

'RHVWKHHQWLW\KDYHDQ\VLWHVIDFLOLWLHVLGHQWLŸ∂HGDVGHVLJQDWHGFRQVXPHUV'&VXQGHUWKH3HUIRUPDQFH$FKLHYHDQG
Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been 
achieved. In case targets have not been achieved, provide the remedial action taken, if any. 
 
Not applicable
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
246
3. 
Provide details of the following disclosures related to water, in the following format:
Parameter 
FY 2024-25
FY 2023-24
:DWHUZLWKGUDZDOE\VRXUFHLQNLOROLWHUV
(i)  
Surface water 
4,036
5,182
(ii)  
Groundwater 
2,88,064
2,65,516
(iii)  Third party water 
2,37,532
2,04,066
(iv)  Seawater / desalinated water 
Nil
Nil
(v)  
Others 
Nil
Nil
Total volume of water withdrawal (in kiloliters) (i + ii + iii + iv + v) 
5,29,632
4,74,764
Total volume of water consumption (in kiloliters) 
5,07,302
4,67,791
Water intensity per rupee of turnover (Total water consumption in KL / 
Revenue from operations in INR Crores) 
55
59
:DWHULQWHQVLW\SHUUXSHHRIWXUQRYHUDGMXVWHGIRU3XUFKDVLQJ3RZHU3DULW\
(PPP) (Total water consumption in KL / Revenue from operations adjusted 
for PPP in USD terms)
1,136
1,328
Water intensity in terms of physical output (KL/MT of production) 
34
31
 
Note: ,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1,I
yes, name of the external agency
 
Yes, reasonable level of assurance for BRSR core indicators has been carried out by an external agency for FY2024-25. The 
H[WHUQDODJHQF\LV'19%XVLQHVV$VVXUDQFH,QGLD3ULYDWH/LPLWHG
4. 
Provide the following details related to water discharged:
Parameter 
FY 2024-25
FY 2023-24
:DWHUGLVFKDUJHE\GHVWLQDWLRQDQGOHYHORIWUHDWPHQWLQNLOROLWHUV
(i) 
To Surface water 
1$
1$
 
-  
No treatment 
1$
1$


:LWKWUHDWPHQW»ÄSOHDVHVSHFLI\OHYHORIWUHDWPHQW
1$
1$
(ii)  
To Groundwater 
1$
1$
 
-  
No treatment 
1$
1$


:LWKWUHDWPHQW»ÄSOHDVHVSHFLI\OHYHORIWUHDWPHQW
1$
1$
(iii)  To Seawater 
1$
1$
 
-  
No treatment 
1$
1$


:LWKWUHDWPHQW»ÄSOHDVHVSHFLI\OHYHORIWUHDWPHQW
1$
1$
(iv)  Sent to third parties 
1$
1$
 
-  
No treatment 
1$
1$


:LWKWUHDWPHQW»Ä7HUWLDU\7UHDWPHQW
22,330
6,973
(v)  
Others 
1$
1$
 
-  
No treatment 
1$
1$


:LWKWUHDWPHQW»ÄSOHDVHVSHFLI\OHYHORIWUHDWPHQW
1$
1$
Total water discharged (in kiloliters) 
22,330
6,973
 
Note:,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1,I
yes, name of the external agency. 
 
Yes, reasonable level of assurance for BRSR core indicators has been carried out by an external agency for FY2024-25. The 
H[WHUQDODJHQF\LV'19%XVLQHVV$VVXUDQFH,QGLD3ULYDWH/LPLWHG
5. 
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation. 

$OO*3/PDQXIDFWXULQJIDFLOLWLHVZLWKWKHH[FHSWLRQRI7DORMDDQG%DGGLKDYHLPSOHPHQWHG=HUR/LTXLG'LVFKDUJH=/'
V\VWHPV RQVLWH :DVWHZDWHU JHQHUDWHG IURP RSHUDWLRQV LV WUHDWHG DQG UHXVHG IRU YDULRXV DFWLYLWLHV LQFOXGLQJ XWLOLW\
RSHUDWLRQVDQGJDUGHQLQJHŸµHFWLYHO\PLQLPL]LQJIUHVKZDWHUFRQVXPSWLRQ
Integrated Annual Report FY 2025
247
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
6. 
Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:
Parameter 
FY 2024-25
FY 2023-24
NOx
120
121
SOx
9
43
Particulate Matter (PM)
71
58
Persistent organic pollutants (POP)
1$
1$
Volatile organic compounds (VOC)
1$
1$
+D]DUGRXVDLUSROOXWDQWV+$3
1$
1$
Others ‚Äì ozone-depleting substances (HCFC - 22 or R-22)
1$
1$

,Q)<ZHUHSRUWHGWKHŸ∂JXUHVIRUWKHPDLQSODQWLQPJ1PXQLWXVLQJWKHODWHVWPRQWKO\UHSRUWDVDUHIHUHQFH
However, this year we are reporting annual data for all our manufacturing plants and R&D centers within the reporting 
boundary in tonnes/annum.
 
Note: ,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1,I
yes, name of the external agency. 
 
No. It is not applicable
7. 
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format: 
Parameter 
Unit 
FY 2024-25 
FY 2023-24
Total Scope 1 emissions 
(Break-up of the GHG into 
CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available) 
Metric 
tons 
of 
CO2 
equivalent 
17,263
15,240
Total Scope 2 emissions*
(Break-up of the GHG into 
CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available) 
Metric 
tons 
of 
CO2 
equivalent 
76,186
69,622
Total Scope 1 and Scope 2 emission intensity per rupee of 
turnover 
(Total Scope 1 and Scope 2 GHG emissions / Revenue from 
operations) 
Metric 
tons 
of 
CO2 equivalent / 
INR Crores
10
11
Total Scope 1 and Scope 2 emission intensity per rupee of 
turnover adjusted for Purchasing Power Parity (PPP) 
(Total Scope 1 and Scope 2 GHG emissions / Revenue from 
operations adjusted for PPP in USD terms)
Metric 
tons 
of 
CO2 
equivalent 
/ 
INR 
Crores 
adjusted for PPP
209
241
Total Scope 1 and Scope 2 emission intensity in terms of physical 
output 
Metric 
tons 
of 
CO2 equivalent / 
MT of Production
6
6

:HKDYHFDOFXODWHGRXU6FRSHHPLVVLRQVXVLQJDPDUNHWEDVHGDSSURDFK
 
Note: ,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1 
If yes, name of the external agency. 
 
Yes, reasonable level of assurance for BRSR core indicators has been carried out by an external agency for FY 2024-25. 
7KHH[WHUQDODJHQF\LV'19%XVLQHVV$VVXUDQFH,QGLD3ULYDWH/LPLWHG
8. 
Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details. 

:H KDYH LQLWLDWHG VHYHUDO SURMHFWV DLPHG DW UHGXFLQJ JUHHQKRXVH JDV HPLVVLRQV DFURVV PXOWLSOH VLWHV $W WKH %DGGL
facility, we have installed a briquette boiler, while both the Goa Main and Hormone sites have transitioned to Piped 
1DWXUDO *DV WR IXOŸ∂OO WKHLU ERLOHU IXHO UHTXLUHPHQWV $GGLWLRQDOO\ *OHQPDUN KDV HQWHUHG LQWR DQ DJUHHPHQW ZLWK 
25HQHZDEOH(QHUJ\;;,93ULYDWH/LPLWHGWRVHFXUHRSHQDFFHVVWRVRODUSRZHUIRULWV&61DQG1DVKLNSODQWV7KLVLQLWLDWLYH
LVH[SHFWHGWRSURYLGHDSSUR[LPDWHO\0:RISRZHUZKLFKZLOODFFRXQWIRUDURXQGRIWKHHOHFWULFLW\FRQVXPHGDW
these facilities. The investment of approximately INR 2 crore is projected to deliver a payback period of about 12 months 
and reduce carbon emissions by approximately 10% of GPL‚Äôs total emissions.
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
248
9. 
Provide details related to waste management by the entity, in the following format:
Parameter 
FY 2024-25 
FY 2023-24
Total waste generated (in metric tons) 
3ODVWLFZDVWH$
276
715
(ZDVWH%
9
3
Bio-medical waste (C) 
26
19
Construction and demolition waste (D) 
167
196
%DWWHU\ZDVWH(
11
6
Radioactive waste (F) 
0
0
2WKHU +D]DUGRXV ZDVWH &KHPLFDO 6OXGJH 'DWH ([SLUHG SURGXFWV 2Ÿµ
6SHFLŸ∂FDWLRQSURGXFWV8VHG6SHQW2LO3URFHVV:DVWHUHVLGXHFRQWDLQLQJ
Oil etc.) Please specify, if any. (G) 
1,220
1,120
Other Non-hazardous waste generated (H). (Uncontaminated Metal & non-
metallic scrap, plastic scrap, wooden scrap, paper scrap, wooden scrap etc.) 
Please specify, if any. 
(Break-up by composition i.e. by materials relevant to the sector) 
2,099
1,772
Total (A+B + C + D + E + F + G + H) 
3,808
3,831
Waste intensity per rupee of turnover 
(Total waste generated in MT / Revenue from operations in INR Crores) 
0.41
0.48
Waste intensity per rupee of turnover adjusted for 
Purchasing Power Parity (PPP) 
(Total waste generated in MT / Revenue from operations adjusted for
PPP in USD terms)
8.53
11
Waste intensity in terms of physical output (Waste generated in MT/
MT of production)
0.26
0.25
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in 
metric tons) 
Category of waste 
(i)  
Recycled 
2,548
2,706
(ii)  
Re-used 
Nil
Nil
(iii)  Other recovery operations 
Nil
Nil
Total 
2,548
2,706
For each category of waste generated, total waste disposed by nature of disposal method (in metric tons) 
Category of waste 
 
 
(i)  
Incineration 
156
163
LL
/DQGŸ∂OOLQJ
0
45
(iii)   Other disposal operations (Pre-processing, Co-processing & Recycling)
1,058
917
Total 
1,214
1,125
 
Note:,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1,I
yes, name of the external agency. 
 
Yes, reasonable level of assurance for BRSR core indicators has been carried out by an external agency for FY2024-25. The 
H[WHUQDODJHQF\LV'19%XVLQHVV$VVXUDQFH,QGLD3ULYDWH/LPLWHG
 %ULHŸ∑\GHVFULEHWKHZDVWHPDQDJHPHQWSUDFWLFHVDGRSWHGLQ\RXUHVWDEOLVKPHQWV'HVFULEHWKHVWUDWHJ\DGRSWHGE\
your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices 
adopted to manage such wastes. 

:HKDYHHVWDEOLVKHGDFRPSUHKHQVLYHZDVWHPDQDJHPHQWSODQDQGVWDQGDUGRSHUDWLQJSURFHGXUHV623VIRUKDQGOLQJ
YDULRXVW\SHVRIZDVWHDFURVVDOOLWVVLWHV:HSULRULWL]HWKHVHJUHJDWLRQRIZDVWHHQHUJ\UHFRYHU\WKURXJKFRSURFHVVLQJ
DQGWKHVDIHGLVSRVDORIDQ\UHVLGXDOZDVWH$SSUR[LPDWHO\RIRXUWRWDOZDVWHLVGLYHUWHGIRUHQHUJ\UHFRYHU\WKURXJK
FRSURFHVVLQJXWLOL]LQJZDVWHDVDQDOWHUQDWLYHIXHO$OOPDQXIDFWXULQJDQG5	'IDFLOLWLHVKDYHVXFFHVVIXOO\DFKLHYHG=HUR
:DVWH7R/DQGŸ∂OOVWDWXV
Integrated Annual Report FY 2025
249
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
 ,IWKHHQWLW\KDVRSHUDWLRQVRŸ∏FHVLQDURXQGHFRORJLFDOO\VHQVLWLYHDUHDVVXFKDVQDWLRQDOSDUNVZLOGOLIHVDQFWXDULHV
biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental 
approvals / clearances are required, please specify details in the following format:
 
Not applicable.
12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the 
FXUUHQWŸ∂QDQFLDO\HDU
 
Not applicable.
13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act 
and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format: 
 
Yes. The Company is compliant with all the applicable environmental laws / regulations / guidelines in India.
Leadership Indicators 
1. 
Water withdrawal, consumption and discharge in areas of water stress (in kiloliters): 
 
For each facility / plant located in areas of water stress, provide the following information: 
 
(i) 
Name of the area: Pithampur
 
(ii) 
Nature of operations: Manufacturing Unit
 
(iii) Water withdrawal, consumption and discharge in the following format: 
Parameter 
FY 2024-25
FY 2023-24 
Water withdrawal by source (in kiloliters) 
(i)  
Surface water 
Nil
Nil
(ii)  
Groundwater 
Nil
Nil
(iii)  Third party water 
1,02,606
1,00,876
(iv)  Seawater / desalinated water 
Nil
Nil
(v)  
Others 
Nil
Nil
Total volume of water withdrawal (in kiloliters) 
1,02,606
1,00,876
Total volume of water consumption (in kiloliters) 
1,02,606
1,00,876
Water intensity per rupee of turnover (Water consumed / revenue from 
operations in INR Crores) 
11
13
Water discharge by destination and level of treatment (in kiloliters) 
(i)  
Into Surface water 
1$
1$
 
-  
No treatment 


:LWKWUHDWPHQW
(ii)  
Into Groundwater 
 
-  
No treatment 


:LWKWUHDWPHQW
(iii)  Into Seawater 
 
-  
No treatment 


:LWKWUHDWPHQW
(iv)  Sent to third parties 
 
-  
No treatment 


:LWKWUHDWPHQW
(v)  
Others 
 
-  
No treatment 


:LWKWUHDWPHQW
Total water discharged (in kiloliters) 
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
250
 
 
Note:,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"
(Y/N) If yes, name of the external agency. 
 
 
No
2. 
Please provide details of total Scope 3 emissions & its intensity, in the following format: 
Parameter 
Unit 
FY 2024-25
FY 2023-24
Total Scope 3 emissions 
(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, 
NF3, if available) 
Metric tons of CO2 
equivalent 
1,56,645
1,70,970
Total Scope 3 emissions per rupee of turnover 
tCO2 eq/Revenue in 
Million INR
17
22
Total Scope 3 emission intensity 
W&2HT)7(
1$
1$
 
Note:,QGLFDWHLIDQ\LQGHSHQGHQWDVVHVVPHQWHYDOXDWLRQDVVXUDQFHKDVEHHQFDUULHGRXWE\DQH[WHUQDODJHQF\"<1 
If yes, name of the external agency. 
 
No. It is not applicable. 
3. 
With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide 
GHWDLOVRIVLJQLŸ∂FDQWGLUHFW	LQGLUHFWLPSDFWRIWKHHQWLW\RQELRGLYHUVLW\LQVXFKDUHDVDORQJZLWKSUHYHQWLRQDQG
remediation activities. 
 
Not applicable

,IWKHHQWLW\KDVXQGHUWDNHQDQ\VSHFLŸ∂FLQLWLDWLYHVRUXVHGLQQRYDWLYHWHFKQRORJ\RUVROXWLRQVWRLPSURYHUHVRXUFH
HŸ∏FLHQF\RUUHGXFHLPSDFWGXHWRHPLVVLRQVHŸπXHQWGLVFKDUJHZDVWHJHQHUDWHGSOHDVHSURYLGHGHWDLOVRIWKH
same as well as outcome of such initiatives, as per the following format: 
Sr. 
No 
Initiative undertaken 
Details of the initiative (Web-link, if any, may be 
provided along-with summary) 
Outcome  of 
the initiative 
1
Switching from thermal 
energy 
to 
renewable 
energy
‚Ä¢ 
Installation of rooftop of solar power plants. 
‚Ä¢ 
 Sourcing of solar energy for Taloja & Mahape 
facilities. 
Reduction of GHG emission 
through sourcing of renewable 
energy
2
Deployment of energy 
HŸ∏FLHQWHTXLSPHQW
Replacement of energy intensive equipment with 
HQHUJ\ HŸ∏FLHQW HTXLSPHQW DQG DXWRPDWLRQ RI
processes to conserve energy sources. 
(QHUJ\FRQVHUYDWLRQ
5. 
Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link. 

<HV ZH KDYH GHYHORSHG D FRPSUHKHQVLYH 'LVDVWHU 0DQDJHPHQW 3ODQ  2QVLWH (PHUJHQF\ 3ODQ WKDW RXWOLQHV YDULRXV
important components, including the organizational structure, factory layout, objectives, processes, process hazards and 
their control measures, natural disaster preparedness, environmental impact assessment, emergency evacuation protocols, 
emergency declaration procedures, plant safe shutdown procedures, and an organogram for the emergency action plan.

7KH&RPSDQ\KDVFOHDUO\GHŸ∂QHGUHVSRQVLELOLWLHVDVVHPEO\SRLQWVPHGLFDODUUDQJHPHQWV0DWHULDO6DIHW\'DWD6KHHWV
06'6H[WHUQDOFRQWDFWQXPEHUVDQGFUXFLDOPXWXDODLGFRQWDFWVWRHQVXUHHŸ∏FLHQWRSHUDWLRQVGXULQJDQ\HPHUJHQF\
 
In the event of business disruptions, we have implemented risk mitigation strategies, complete with standard operating 
procedures and detailed guidelines outlining roles and responsibilities, as well as action plans for timely responses. These 
SODQVDUHWDLORUHGWRDGGUHVVFRPPRQO\LGHQWLŸ∂HGEXVLQHVVGLVUXSWLRQULVNVIRFXVLQJRQDVSHFWVVXFKDV»àUHVSRQGLQJWR»â
»àPLWLJDWLQJWKHHŸµHFWVRI»âDQG»àUHVWRULQJ»âRSHUDWLRQVVDIHO\DQGUHVSRQVLEO\7KHDFWLRQSODQVLQFOXGHVSHFLŸ∂FPHDVXUHVWR
DGGUHVVLGHQWLŸ∂HGULVNVDLPLQJWRSUHYHQWFDVXDOWLHVDQGLQMXULHVIDFLOLWDWHVZLIWUHOLHIDQGUHVFXHRSHUDWLRQVDVQHHGHG
and expedite the return to normal operations.

0RUHRYHUDOOHPSOR\HHVDQGFRQWUDFWZRUNHUVUHFHLYHWUDLQLQJWRHŸµHFWLYHO\UHVSRQGWRHPHUJHQFLHVRUGLVDVWHUV

'LVFORVH DQ\ VLJQLŸ∂FDQW DGYHUVH LPSDFW WR WKH HQYLURQPHQW DULVLQJ IURP WKH YDOXH FKDLQ RI WKH HQWLW\ :KDW
mitigation or adaptation measures have been taken by the entity in this regard. 
 
No adverse impact to the environment arising from our value chain. 
Integrated Annual Report FY 2025
251
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
7. 
Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.

2XW RI  VXSSOLHUV IRU UDZ PDWHULDOV DQG SDFNDJLQJ PDWHULDOV  DUH FODVVLŸ∂HG DV FULWLFDO VXSSOLHUV IRU ZKRP WKH
Company has assessed environmental impacts. These critical suppliers account for 90% of the total value of business 
among our value chain partners.
8. 
How many Green Credits have been generated or procured:
 
Nil
35,1&,3/(  %XVLQHVVHV ZKHQ HQJDJLQJ LQ LQŸ∑XHQFLQJ SXEOLF DQG UHJXODWRU\ SROLF\ VKRXOG GR VR LQ D
manner that is responsible and transparent 
Essential Indicators 

D
1XPEHURIDŸ∏OLDWLRQVZLWKWUDGHDQGLQGXVWU\FKDPEHUVDVVRFLDWLRQV
 
 
7
 
b. 
List the top 10 trade and industry chambers/ associations (determined based on the total members of such 
ERG\WKHHQWLW\LVDPHPEHURIDŸ∏OLDWHGWR
Sr. 
No.
Name of the trade and industry chambers/ associations
Reach of trade and industry 
chambers/ associations (State/
National)
1.
,QGLDQ3KDUPDFHXWLFDO$OOLDQFH,3$
National
2.
,QGLDQ'UXJ0DQXIDFWXUHUV»Ö$VVRFLDWLRQ,'0$
National
3.
3KDUPDFHXWLFDOV([SRUW3URPRWLRQ&RXQFLO3+$50(;&,/
National
4.
Federation of Indian Chambers of Commerce and Industry (FICCI)
National
5.
)HGHUDWLRQRI3KDUPD(QWUHSUHQHXUV)23(
National
6.
Bombay Chamber of Commerce and Industry (BCCI)
State
7.
Swiss-Indian Chamber of Commerce (SICC)
National
2. 
Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the 
entity, based on adverse orders from regulatory authorities. 
Name of authority
Brief of the case
Corrective action taken
1RW$SSOLFDEOH
Leadership Indicators
1. 
Details of public policy positions advocated by the entity: 
Sr. 
No. 
Public policy advocated 
Method 
resorted 
for 
such advocacy 
Whether 
information 
available 
in public 
domain? (Yes/
No) 
Frequency of 
Review by Board 
(Annually/ Half 
yearly/ Quarterly 
/ Others) 
Web 
Link, if 
available 
 
1
Strengthening innovation and 
pharmaceutical R&D landscape 
of the domestic pharmaceutical 
sector
Representation 
directly 
and 
through 
industry 
associations
No
Periodically
1$
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
252
Sr. 
No. 
Public policy advocated 
Method 
resorted 
for 
such advocacy 
Whether 
information 
available 
in public 
domain? (Yes/
No) 
Frequency of 
Review by Board 
(Annually/ Half 
yearly/ Quarterly 
/ Others) 
Web 
Link, if 
available 
 
2
Focus 
on 
quality 
and 
strengthening 
regulatory 
measures 
against 
spurious/ 
counterfeit 
products 
in 
the 
market
Representation 
directly 
and through associations
No
Periodically
1$
3
$GYRFDF\
RQ
UDWLRQDOL]DWLRQ
of 
regulatory 
procedures, 
pharmaceutical pricing, reducing 
global 
trade 
related 
barriers 
to 
ensure 
timely 
access 
to 
DŸµRUGDEOHPHGLFLQHV
Representation 
through 
associations
No
Periodically
1$
PRINCIPLE 8 Businesses should promote inclusive growth and equitable development 
Essential Indicators 
1. 
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the 
FXUUHQWŸ∂QDQFLDO\HDU

1RW$SSOLFDEOH
2. 
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by 
your entity, in the following format: 

1RW$SSOLFDEOH
3. 
Describe the mechanisms to receive and redress grievances of the community. 
 
The CSR partners regularly interact with local communities to address grievances and provide solutions. They also organize 
awareness campaigns and oversee the execution of various Corporate Social Responsibility (CSR) projects and initiatives.
4. 
Percentage of input material (inputs to total inputs by value) sourced from suppliers: 
Particulars
FY 2024-25
FY 2023-24 
'LUHFWO\VRXUFHGIURP060(VPDOOSURGXFHUV
7%
7%
Directly from within India
70%
78%
5. 
Job creation in smaller towns ‚Äì Disclose wages paid to persons employed (including employees or workers employed 
on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost.
Location 
FY 2024-25
FY 2023-24 
Rural 
0.02%
0.03%
Semi-urban 
11.60%
11.16%
Urban 
22.48%
23.41%
Metropolitan 
65.90%
65.40%
Leadership Indicators 

3URYLGHGHWDLOVRIDFWLRQVWDNHQWRPLWLJDWHDQ\QHJDWLYHVRFLDOLPSDFWVLGHQWLŸ∂HGLQWKH6RFLDO,PSDFW$VVHVVPHQWV
(Reference: Question 1 of Essential Indicators above): 

1RW$SSOLFDEOH
Integrated Annual Report FY 2025
253
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
2. 
Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as 
LGHQWLŸ∂HGE\JRYHUQPHQWERGLHV

,QWKHŸ∂QDQFLDO\HDU»ÄZHVXFFHVVIXOO\LPSOHPHQWHG&65LQLWLDWLYHVLQWKHDVSLUDWLRQDOGLVWULFWVRI.KDQGZD0DGK\D
3UDGHVK1DQGXUEDU0DKDUDVKWUD.KXQWL-KDUNKDQGDQG'DUUDQJ$VVDPUHDŸ∏UPLQJRXUFRPPLWPHQWWRLQFOXVLYHDQG
sustainable community development in underserved regions.
3. 
(a) 
Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalized /vulnerable groups? (Yes/No) 
 
 
No, the Company does not have any preferential procurement policy.
 
b) 
From which marginalized /vulnerable groups do you procure? 


1RW$SSOLFDEOH
 
(c) 
What percentage of total procurement (by value) does it constitute? 


1RW$SSOLFDEOH

'HWDLOVRIWKHEHQHŸ∂WVGHULYHGDQGVKDUHGIURPWKHLQWHOOHFWXDOSURSHUWLHVRZQHGRUDFTXLUHGE\\RXUHQWLW\LQWKH
FXUUHQWŸ∂QDQFLDO\HDUEDVHGRQWUDGLWLRQDONQRZOHGJH
S. No. 
Intellectual Property based on 
traditional knowledge 
Owned/ Acquired 
(Yes/No) 
%HQHŸ∂WVKDUHG
(Yes / No) 
Basis of calculating 
EHQHŸ∂WVKDUH
1RW$SSOLFDEOH
5. 
Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes 
wherein usage of traditional knowledge is involved. 
Name of the Authority
Brief of the case
Corrective action taken
1RW$SSOLFDEOH

'HWDLOVRIEHQHŸ∂FLDULHVRI&653URMHFWV
CSR Project
1RRISHUVRQVEHQHŸ∂WWHG
from CSR Projects
RIEHQHŸ∂FLDULHVIURPYXOQHUDEOH
and marginalized groups
'HWDLOVRIWKHEHQHŸ∂FLDULHVLPSDFWHGWKURXJKRXU&65LQLWLDWLYHVDUHSUHVHQWHGLQWKH»Ñ6RFLDODQG5HODWLRQVKLS&DSLWDO»Ö
VHFWLRQRIWKLV,QWHJUDWHG5HSRUW2XU&65HŸµRUWVDUHGHVLJQHGWRVHUYHWKHHFRQRPLFDOO\DQGVRFLDOO\GLVDGYDQWDJHG
communities across both rural and urban geographies.
PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner
Essential indicators
1. 
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

:HKDYHHVWDEOLVKHGFOHDUPHFKDQLVPVWRFDSWXUHIHHGEDFNDQGUHVSRQGHŸµHFWLYHO\WRFRQVXPHUFRQFHUQVSURPSWO\DFURVV
all markets where we operate. These include: 

»ç
0XOWLSOH$FFHVV3RLQWV&RQVXPHUVFDQUDLVHSURGXFWUHODWHGFRQFHUQVWKURXJKRXUFRPPRQPDLOER[GHWDLOVFDQEH
IRXQGRQRXUFRUSRUDWHZHEVLWHRUYLDORFDOFRXQWU\RŸ∏FHZHEVLWHVSKRQHQXPEHUVDQGGHGLFDWHGPDLOER[HV

»ç
'HGLFDWHG+HOSOLQHV:HKDYHFDOOFHQWHUVLQWKH86$,QGLD8.1HWKHUODQGVDQG*HUPDQ\WRSURYLGHGLUHFWVXSSRUW
for complaints and feedback from consumers in these regions.

»ç
$FWLYH)ROORZXS(DFKFRPSODLQWLVPRQLWRUHGZLWKWKHKHOSRIGHGLFDWHGWHDPVLQWKHUHVSHFWLYHFRXQWU\2XUORFDO
SKDUPDFRYLJLODQFHVWDŸµUHDFKHVRXWIRUFRQVHQWDQGIXUWKHUGHWDLOVZKHQQHHGHGWRHQVXUHDFRPSOHWHXQGHUVWDQGLQJ
of the issue.

»ç
7UDQVSDUHQW5HVROXWLRQ$IWHUUHVROYLQJDFRPSODLQWWKHFRQVXPHULVLQIRUPHGRIWKHRXWFRPHFORVLQJWKHORRSZLWK
clarity.
Glenmark Pharmaceuticals Limited
Business Responsibility and Sustainability Report (BRSR)
254
2. 
Turnover of products and/ services as a percentage of turnover from all products/service that carry information 
about: 
Particulars
As a percentage of total turnover
(QYLURQPHQWDODQGVRFLDOSDUDPHWHUVUHOHYDQWWRWKHSURGXFW
100%
Safe and responsible usage
100%
Recycling and /or safe disposal
100%
3. 
Number of consumer complaints in respect of the following: 
Particulars
FY 2024-25
FY 2023-24
Received 
during the 
year 
Pending 
resolution 
at the end 
of the year
Remarks
Received 
during the 
year
Pending 
resolution 
at the end 
of the year
Remarks
Data privacy 
Nil
Nil
1$
Nil
Nil
1$
$GYHUWLVLQJ
Nil
Nil
1$
Nil
Nil
1$
Cybersecurity
Nil
Nil
1$
Nil
Nil
1$
Delivery of essential services 
Nil
Nil
1$
Nil
Nil
1$
Restrictive trade practices
Nil
Nil
1$
Nil
Nil
1$
Unfair trade practices
Nil
Nil
1$
Nil
Nil
1$
Others
3,717
365
1$
2,666
356
1$
4. 
Details of instances of product recalls on account of safety issues:
Number
Reason for Recall
Voluntary Recall
24
2XWRI6SHFLŸ∂FDWLRQIRUYDULRXVWHVWV1LWURVDPLQH,PSXULWLHVDQG3URGXFWTXDOLW\
complaints.
Forced Recall
0
-
5. 
Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, 
provide a web-link of the policy 

<HVZHKDYHZHOOGHŸ∂QHGSROLFLHVDQGSURFHGXUHVLQSODFHWRVDIHJXDUGVHQVLWLYHPHGLFDODQGSHUVRQDOLQIRUPDWLRQDQG
prevent unauthorized access. Our Privacy Policy and related protocols are accessible to employees and relevant stakeholders 
via the Company‚Äôs intranet.
6. 
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential 
services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action 
taken by regulatory authorities on safety of products / services.

1RW$SSOLFDEOH
7. 
Provide the following information relating to data breaches: 
 
a. 
Number of instances of data breaches - Nil

E
3HUFHQWDJHRIGDWDEUHDFKHVLQYROYLQJSHUVRQDOO\LGHQWLŸ∂DEOHLQIRUPDWLRQRIFXVWRPHUV- Nil
 
c. 
Impact, if any, of the data breaches 
 
Nil, no incidents of data breaches occurred.
Integrated Annual Report FY 2025
255
Financial Statements
Statutory Reports
Business Responsibility and Sustainability Report (BRSR)
Corporate Overview
Leadership Indicators
1. 
Channels / platforms where information on products and services of the entity can be accessed (provide web link, if 
available). 
 
https://glenmarkpharma.com/product-overview/
2. 
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services. 

:HFRPSO\ZLWKDOOUHOHYDQWUHJXODWRU\UHTXLUHPHQWVE\SURYLGLQJRXUVWDNHKROGHUVZLWKLQIRUPDWLRQRQWKHDSSURSULDWH
and safe use of our products. Safe usage details are mentioned on all our product packaging and labels.
3. 
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services. 

:HKDYHGHŸ∂QHGSURFHVVHVWRLQIRUPVWDNHKROGHUVDERXWDQ\ULVNRIGLVUXSWLRQRUGLVFRQWLQXDWLRQRIRXUSURGXFWV

»ç
,QOLQHZLWKUHJXODWRU\UHTXLUHPHQWVLQFOXGLQJWKRVHVHWE\WKH1DWLRQDO3KDUPDFHXWLFDO3ULFLQJ$XWKRULW\ZHLVVXH
a public notice for relevant stakeholders and inform the Government in advance before discontinuing any scheduled 
formulation.
 
‚Ä¢ 
In order to ensure minimum disruption of access of medicines to patients, the Company has also implemented certain 
anti- counter feating measures for some of the critical products.

»ç
$VZHRSHUDWHLQDZHOOHVWDEOLVKHGPDUNHWZKHUHWKHUDSHXWLFDOWHUQDWLYHVDUHUHDGLO\DYDLODEOHFRQWLQXLW\RIFDUHLV
ensured even in the event of a product discontinuation.
 
 
No major disruption or discontinuation of our services was reported in FY 2025.
4. 
Does the entity display product information on the product over and above what is mandated as per local laws? 
(Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to consumer 
VDWLVIDFWLRQUHODWLQJWRWKHPDMRUSURGXFWVVHUYLFHVRIWKHHQWLW\VLJQLŸ∂FDQWORFDWLRQVRIRSHUDWLRQRIWKHHQWLW\RU
the entity as a whole? (Yes/No) 
 
Our product labelling complies with all applicable regulatory requirements, and includes additional information where 
UHTXLUHGEDVHGRQWKHQDWXUHRIWKHSURGXFWDQGLWVSDFNDJLQJb

:HDOVRWUDFNFXVWRPHUVDWLVIDFWLRQWKURXJKVHUYLFHOHYHOVXUYH\VDQGRQJRLQJPRQLWRULQJWRHQVXUHVHUYLFHH[FHOOHQFH
%H\RQGVXUYH\VZHJDWKHUIHHGEDFNWKURXJK$QQXDO3DUWQHUVKLS+HDOWK&KHFNVLQRXU%%HQJDJHPHQWV2XU0HGLFDO
$ŸµDLUV WHDP VWD\V LQ UHJXODU WRXFK ZLWK KHDOWKFDUH SURIHVVLRQDOV ZKLOH ZH DOVR HQJDJH ZLWK SDWLHQW JURXSV WR EHWWHU
understand their needs. Feedback from consumers is managed by our Medical Information and PV teams to support timely 
action and continuous improvement.
Glenmark Pharmaceuticals Limited
Assurance Statement
256
Statement Number: DNV-2025-ASR-812813-1
Page  of 
DNV Headquarters, Veritasveien 1, P.O.Box 300, 1322 H√∏vik, Norway. Tel: +47 67 57 99 00. www.dnv.com
DNV Business Assurance India Private Limited
to the Management of Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited (Corporate Identity Number L24299MH1977PLC019982, (hereafter referred to as ‚ÄòGlenmark‚Äô 
or ‚Äòthe Company‚Äô) has commissioned DNV Business Assurance India Private Limited (‚ÄòDNV‚Äô, ‚Äòus‚Äô or ‚Äòwe‚Äô) to undertake an 
independent assurance of the Company‚Äôs disclosures in its Business Responsibility and Sustainability Report (hereafter referred
to as ‚ÄòBRSR‚Äô) for the Financial Year (FY) 2024-25. The disclosures include the BRSR Core attributes as per Annexure 17A of Master 
Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 11, 2024.
Scope of Work and Boundary
The scope of our engagement includes a reasonable level of assurance of the ‚Äò9 
BRSR Core Attributes‚Äô for the FY 2024-25. 
Boundary for the engagement covers the performance of Glenmark‚Äôs operations
in India that fall under the direct operational control of the Company‚Äôs Legal 
structure. Based on the agreed scope with the Company, the boundary of 
reasonable assurance covers the operations of Glenmark in India which includes 1 
Head office, 7 manufacturing locations and 3 R&D centers and other offices located 
in India for BRSR core attributes 5-9. For BRSR core attributes 1-4, the boundary is
10 sites in India covering Company‚Äôs 7 manufacturing locations and 3  R&D centers. 
Reporting Criteria and Standards
The disclosures have been prepared by Glenmark in reference to:
x
Industry 
Standard 
on 
Reporting 
of 
BRSR 
Core,
Circular 
No.: 
SEBI/HO/CFD/CFD-PoD-1/P/CIR/2024/177 dated Dec 20, 2024.
x
BRSR Core (Annexure 17A) and BRSR reporting guidelines (Annexure 16) as 
per Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 
11, 2024.
x
The Greenhouse Gas Protocol: A Corporate Accounting and Reporting 
Standard.
Assurance Methodology/Standard and Level of Assurance
This assurance engagement for reasonable level of assurance has been carried out 
in accordance with DNV‚Äôs VeriSustainTM protocol, V6.0, which is based on our 
professional experience and international assurance practice, and the international 
standard in Assurance Engagements, ISAE 3000 (revised)- Assurance Engagements 
other than Audits or Reviews of Historical Financial Information. DNV‚Äôs VeriSustainTM
Protocol, V6.0 has been developed in accordance with the most widely accepted 
reporting and assurance standards. 
Apart from DNV‚Äôs VeriSustainTM protocol (V6.0), DNV team has also followed ISO 14064-3 - Specification with guidance for the 
verification and validation of greenhouse gas statements; ISO 14046 - Environmental management - Water footprint - Principles, 
requirements, and guidelines, to evaluate disclosure wrt. Greenhouse gases and water disclosures respectively.
Basis of our conclusion
As part of the assurance process, a multi-disciplinary team of assurance specialists performed assurance work for selected sites 
of Glenmark. We carried out the following activities:
x
Reviewed the disclosures under BRSR Core, encompassing the framework for assurance consisting of a set of Key 
Performance Indicators (KPIs) under 9 ESG attributes. The Industry Standard on Reporting of BRSR Core used a basis of 
reasonable level of assurance.
x
Evaluation of the design and implementation of key systems, processes and controls for collecting, managing and reporting 
the BRSR Core indicators. Assessment of operational control and reporting boundaries.
x
Seek extensive evidence across all relevant areas, ensuring a detailed examination of BRSR Core indicators. Engaged directly 
with stakeholders to gather insights and corroborative evidence for each disclosed indicator.
Our competence, and Independence
Our Conclusion: 
Based on our review and procedures followed for a reasonable level of assurance, DNV is of the opinion that, 
in all material aspects, the BRSR Core Key Performance Indicators (KPIs) under 9 ESG attributes (as listed in 
Annexure I of this statement) for the FY 2024-25 are reported in accordance with reporting requirements 
outlined in the Industry Standard on Reporting of BRSR Core.
Integrated Annual Report FY 2025
257
Financial Statements
Statutory Reports
Assurance Statement
Corporate Overview
Statement Number: DNV-2025-ASR-812813-1
Page  of 
DNV Business Assurance India Private Limited
x
DNV audit team conducted on-site audits for data testing and to assess the uniformity in reporting processes and also, quality 
checks at different locations of the Company. Sites for data testing and reporting system checks were selected based on the 
percentage contribution each site makes to the reported indicator, complexity of operations at each location 
(high/low/medium) and reporting system within the organization. Sites selected for audits are listed in Annexure II.
x
Interviews with selected senior managers responsible for management of disclosures and review of selected evidence to 
support environmental KPIs and metrics disclosed in the Report. We were free to choose interviewees and interviewed those 
with overall responsibility of monitoring, data collation and reporting the selected indicators.
x
Verification of the consolidated reported performance disclosures in context to the Principle of Completeness as per 
VeriSustainTM Protocol, V6.0 for reasonable level of assurance for the disclosures.
Inherent Limitations
DNV‚Äôs assurance engagement assume that the data and information provided by the Company to us as part of our review have been
provided in good faith, is true, complete, sufficient, and authentic, and is free from material misstatements. The assurance scope has 
the following limitations: 
x
The assurance engagement considers an uncertainty of ¬±5% based on materiality threshold for estimation/measurement errors and omissions. 
x
DNV has not been involved in evaluation or assessment of any financial data/performance of the company. DNV opinion on specific BRSR Core 
indicators (for total revenue from operations; Principle 3, Question 1(c) of Essential Indicators for Spending on measures towards well-being of 
employees and workers ‚Äì cost incurred as a % of total revenue of the company; Principle 8, Question 4 of Essential Indicators, Principle 1, Question 
8 of Essential Indicators and Principle 1, Question 9 of Essential Indicators) relies on the third party audited financial reports of the Company. DNV 
does not take any responsibility of the financial data reported in the audited financial reports of the Company. 
x
The assessment is limited to data and information within the defined Reporting Period. Any data outside this period is not considered within the 
scope of assurance.
x
Data outside the operations specified in the assurance boundary is excluded from the assurance, unless explicitly mentioned otherwise in this 
statement.
x
The assurance does not cover the Company's statements that express opinions, claims, beliefs, aspirations, expectations, aims, or future 
intentions. Additionally, assertions related to Intellectual Property Rights and other competitive issues are beyond the scope of this assurance.
x
The assessment does not include a review of the Company's strategy or other related linkages expressed in the Report. These aspects are not 
within the scope of the assurance engagement.
x
The assurance does not extend to mapping the Report with reporting frameworks other than those specifically mentioned. Any assessments or 
comparisons with frameworks beyond the specified ones are not considered in this engagement.
x
Aspects of the Report that fall outside the mentioned scope and boundary are not subject to assurance. The assessment is limited to the defined 
parameters.
x
The assurance engagement does not include a review of legal compliances. Compliance with legal requirements is not within the scope of this 
assurance, and the Company is responsible for ensuring adherence to relevant laws.
Responsibility of the Company
Glenmark has the sole responsibility for the preparation of the BRSR and is 
responsible for all information disclosed in the BRSR Core and BRSR. The 
company is responsible for maintaining processes and procedures for collecting, 
analyzing and reporting the information and also ensuring the quality and 
consistency of the information presented in the Report. Glenmark is also 
responsible for ensuring the maintenance and integrity of its website and any 
referenced BRSR disclosures on their website. 
DNV‚Äôs Responsibility
In performing this assurance work, DNV‚Äôs responsibility is to the Management of 
the Company; however, this statement represents our independent opinion and 
is intended to inform the outcome of the assurance to the stakeholders of the 
Company. DNV disclaims any liability or co-responsibility for any decision a 
person or entity would make based on this assurance statement.
For DNV Business Assurance India Private Limited,
Ankita Parab
Lead Verifier
Anjana Sharma
Assurance Reviewer
Assurance Team: Varsha Bohiya, Himanshu Babbar, Syed Rameez
26/08/2025, Mumbai, India.
Use and distribution of Assurance statement
Parab, Ankita
Digitally signed by 
Parab, Ankita 
Date: 2025.08.26 
19:18:48 +05'30'
Sharma, 
Anjana
Digitally signed by Sharma, 
Anjana 
Date: 2025.08.26 19:35:36 
+05'30'
Glenmark Pharmaceuticals Limited
Assurance Statement
258
Statement Number: DNV-2025-ASR-812813-1 
 
 
 
Page  of  
 
 
 
DNV Business Assurance India Private Limited 

Annexure I 
 
BRSR Core KPIs  - reasonable level of assurance 
 
BRSR Core Attribute 
Cross- reference to the BRSR 
Attribute1: Green-house gas (GHG) footprint* 
Section C:  Principle 6- Essential Indicator 7* 
Attribute 2: Water footprint 
Section C:  Principle 6- Essential Indicator 3, 4 
Attribute 3: Energy footprint 
Section C:  Principle 6- Essential Indicator 1 
Attribute 4: Embracing circularity - details related to waste 
management by the entity 
Section C:  Principle 6- Essential Indicator 9 
Attribute 5: Enhancing Employee Wellbeing and Safety 
Section C:  Principle 3- Essential Indicator 1-c, 11 
Attribute 6: Enabling Gender Diversity in Business 
Section C:  Principle 5- Essential Indicator 3-b, 7 
Attribute 7: Enabling Inclusive Development 
Section C:  Principle 8- Essential Indicator 4, 5 
Attribute 8: Fairness in Engaging with Customers and Suppliers 
Section C:  Principle 9- Essential Indicator 7, Section C:  Principle 
1- Essential Indicator 8 
Attribute 9: Open-ness of business 
Section C:  Principle 1- Essential Indicator 9 
 
* Scope 1 GHG emissions are calculated based on 2006 IPCC Guidelines for National Greenhouse Gas Inventories, IPCC sixth assessment report and GHG Protocol 
2024. Scope 2 emissions are reported based on market-based approach. Scope 2 GHG emissions for Indian operations are calculated based on the Grid Electricity 
EF - Central Electricity Authority, Govt. of India, CO2 baseline database for Indian Power Sector, version 20, December 2024. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integrated Annual Report FY 2025
259
Financial Statements
Statutory Reports
Assurance Statement
Corporate Overview
Statement Number: DNV-2025-ASR-812813-1 
 
 
 
Page  of  
 
 
 
DNV Business Assurance India Private Limited 
 
 
 
 
Annexure II  
Sites selected for audits 
 
S.no 
Site 
Location 
1. 
Corporate Office 
   Mumbai 
2. 
Manufacturing plants- on-site audit    Goa, Nashik, Baddi, Taloja 
3.  
Manufacturing plants- remote audit    Indore 
 
 
